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Streptococcus pneumoniae is a significant human pathogen and the leading cause of
community-acquired pneumonia and acute otitis media. One of the primary defense mechanisms
of the human immune system against pneumococcal infection involves granule-mediated killing
of bacterial cells by neutrophils. While this mechanism has previously been shown to kill about
half of pneumococci in vitro, we hypothesized that some pneumococcal strains have evolved to
be more resistant to this granule-mediated killing. Clinical isolates demonstrated a varying range
of sensitivity to neutrophil granules. Additionally, we established that the absence of the capsule
may affect sensitivity as unencapsulated isolates showed a higher average survival than
encapsulated isolates. Finally, pneumococcal surface protease HtrA was found to potentially
serve as a protective factor as many knockouts were more sensitive than the wildtypes,
recombinant HtrA protected wildtype TIGR4, and a resistant isolate showed higher htrA
expression levels than sensitive isolates.
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CHAPTER I
INTRODUCTION
Streptococcus pneumoniae (pneumococcus) is a significant, Gram positive, alphahemolytic human pathogen and the leading cause of community-acquired pneumonia and
acute otitis media in children worldwide. Many healthy individuals are asymptomatically
colonized by pneumococcus intermittently throughout their lives. In fact, roughly 50% of
humans are colonized by pneumococcus at any given time (Austrian, 1986). Colonization
occurs in the nasopharynx via inhalation of contaminated aerosolized particles, and
colonization can occur in children as young as two months (Sisson et al., 2000). Children
living in or commonly frequenting densely populated areas or in tight quarters, such as
daycares or orphanages, creates an ideal situation for the transmission of this organism
(Raymond et al., 2000). Transmission of pneumococcus is not restricted to children,
though, as healthy adults can also transmit the bacteria, and it is this cycle of transmission
via colonization without causing disease that has made S. pneumoniae such a prevalent
organism worldwide (Donkor, 2013).
However, colonization of pneumococcus in the susceptible youth, elderly, and
immunocompromised can lead to severe invasive disease, including pneumonia,
meningitis, and sepsis (Bogaert et al., 2004). Disease typically occurs when the organism
disseminates from the nasopharynx into either the blood or lungs, leading to one of the
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diseases listed above. A common pathology seen especially with children is when the
organism spreads to the middle ear resulting in otitis media.
Adherence to and replication of Streptococcus pneumoniae in the alveolar tissue of
the lungs leads to pneumonia. Pneumococcal pneumonia is the most common cause of
pneumonia in children worldwide (CDC). Pneumonia is complicated by the accumulation of
edema fluid in the alveoli in response to bacterial presence and pneumococcal
pneumolysin production (Canvin et al., 1995). A number of different bacterial mechanisms
and interactions with host immune cells determines whether or not the alveolar spaces are
the final location of pneumococcal infection. If the immune response overcomes the
bacteria’s defense mechanisms, the infection can be cleared in the lungs. If the bacteria
persist in the lungs, they can invade the bloodstream causing bacteremia. Replicating
pneumococci circulating through the blood causes septicemia. During this circulation, the
bacteria can make contact with vascular endothelial cells at the blood-brain barrier and
cross the tight junctions into the cerebral spinal fluid (Henriques-Normark and Tuomanen,
2013). This process is initiated via the binding of pneumococcal adhesin choline binding
protein A and host laminin receptor (Orihuela et al., 2009). Then, pneumococcal
phosphorylcholine interacts with the platelet activating factor receptor to cross the bloodbrain barrier (Cundell et al., 1995). After traversing this barrier, pneumococci can enter the
meninges and cause the most severe manifestation of pneumococcal disease, meningitis.
A number of virulence factors play key roles in the pathogenesis of pneumococcal
pneumonia. One of the primary virulence factors of pneumococcus is an extracellular
polysaccharide capsule, which protects against complement and other phagocytic defense
mechanisms (Hyams et al., 2010). Pneumococcus expresses over 90 different capsular
2

serotypes. The capsule is essential in colonization of the nasopharynx as clinically
important type 2 and 3 strains require capsule expression for colonization (Magee and
Yother, 2001). Furthermore, different capsule types play different roles in the progression
from colonization to disease (Kadioglu et al., 2002). The capsule, no matter what type, is
the primary effector in pneumococci evading opsonophagocytosis by immune cells (Cross,
1990).
A successful conjugate vaccine eliciting immunity to the polysaccharide capsule is
available; however, it is not easily available or affordable to those in developing countries.
Despite vaccination efforts, colonization rates have remained constant and around 800,000
children under the age of five die every year due to pneumococcal disease (Bogaert et al.,
2004; O’brien et al., 2009).
One of the primary immune defenses against pneumococcal infection is the
neutrophil. Neutrophils are granulocytes which can kill invading pathogens via a number of
different mechanisms, including phagocytosis, release of granular proteases and
antimicrobial peptides, reactive oxygen-mediated killing, and release of neutrophil
extracellular traps (NETS) (Nauseef, 2007; Brinkmann et al., 2004). Phagocytosis leads
these mechanisms of killing as the primary function of the neutrophil.
Prior to neutrophil killing, however, is the process of neutrophil recruitment and
activation. Neutrophils are recruited to combat pneumococcus immediately following
colonization and throughout invasive infection (Dallaire et al., 2001; Rossum et al., 2005).
They make up the majority of the leukocytes circulating in the blood. When an infection
occurs in the tissue, chemokines released by resident macrophages attract neutrophils to
the site of infection. Then, neutrophils cross into infected tissues via diapedesis at the post3

capillary venules (Kaufmann et al., 2004). Once inside the tissue, the neutrophil uses an
array of pattern recognition receptors (PRRs) to identify and bind to invading pathogens.
In the case of pneumococcal infection, the PRR TLR-2 recognizes and binds pneumococcal
lipoteichoic acid (Schroder et al., 2003). In addition to this binding, pneumolysin can be
recognized and bound by TLR-4 of the neutrophil (Malley et al., 2003). Traditionally, this is
where phagocytosis begins to engulf and degrade pathogens. This process is complex and is
often aided by opsonizing complement proteins and antibodies. In addition to
phagocytosis, though, receptor binding of opsonized material can also lead to the release of
neutrophil granule contents (known as degranulation) and the production of reactive
oxygen compounds (Kaufmann et al., 2004).
The mode in which neutrophils clear pneumococcal infection was initially not well
characterized. However, reactive oxygen-mediated killing was ruled out as neutrophils’
primary method of killing pneumococcus, and other catalase negative organisms, as
patients with reduced reactive oxygen species were unaffected by pneumococcal
colonization (Kaplan et al., 1968). Though the other mechanisms the neutrophil uses to kill
pneumococcus often succeed, the pathogen has developed its own defenses to counteract
those of the neutrophil. The capsule of pneumococcus prevents phagocytosis. It has also
been shown that the negative charge of some capsule types deters nonopsonic killing of
pneumococcus by neutrophils (Li et al., 2013). The capsule has also been shown to inhibit
the microbicidal functions of NETs (Wartha et al., 2007). Likewise, a couple extracellular
vesicle-associated DNases, EndA and TatD, provide S. pneumoniae with resistance to NETs
(Beiter et al., 2006; Jhelum et al., 2018). However, mechanisms providing protection of the
pneumococcus against granule-mediated killing have not been adequately investigated.
4

The release of toxic granules by the neutrophil conventionally occurs during
phagocytosis, when the granules are released into the phagolysosome to degrade the
engulfed pathogens. However, granules can also be released into the extracellular matrix
during phagocytosis or to aid in breakdown of material too large to be ingested (Weiss,
1989). The primary neutrophil granules, or azurophilic granules, contain toxic enzymes
such as cathepsins, defensins, elastase, and myeloperoxidase. Lactoferrin and gelatinase
are components of secondary granules, also known as specific granules, which are
generally less toxic than azurophilic granules. Standish and Weiser (2009) demonstrated
that release of azurophilic granule serine proteases, particularly cathepsin G and elastase,
is the neutrophil’s primary method of killing pneumococcus.
The sequential stimulation with cytochalasin B and formyl-methionyl-leucylphenylalanine (fMLP) was found to artificially degranulate human neutrophils in vitro
(Bentwood and Henson, 1980). Standish and Weiser utilized this artificial stimulation to
extract the azurophilic granules from human neutrophils and subsequently test their
abilities to kill Streptococcus pneumoniae. They found that this extract significantly killed
type 6A pneumococci (2009). Furthermore, they found that this killing by granules was due
to protease activity as three different pneumococcal isolates of different capsule types
showed significant increases in survival to opsonophagocytosis by neutrophils pre-treated
with protease inhibitors (2009). Elastase and cathepsin G, two well-characterized serine
proteases found in neutrophil granules, were found in high amounts in the degranulated
neutrophil extract. Additionally, Standish and Weiser established concentrations of each of
these proteases that significantly killed type 6A pneumococci. This led to their conclusion
5

that these two serine proteases were the primary effectors of intracellular degradation of
pneumococci by human neutrophils (Standish and Weiser, 2009).
Despite a defined mode of neutrophil-mediated killing, Streptococcus pneumoniae
remains a deadly pathogen affecting millions of people worldwide. Therefore, this
organism is able to overcome many neutrophil defenses. However, the mechanism
pneumococci utilize to resist this granule-mediated defense by neutrophils has not been
defined, nor has the conservation of granule-mediated killing across clinical isolates been
determined.
We hypothesized sensitivity to granule-mediated killing would vary across
pneumococcal strains and that many pneumococcal isolates express one or more factors
which confer resistance to neutrophil granule-mediated killing. This work is the first of its
kind to establish a standard sensitivity rate of a panel of clinical isolates, which represent
an array of different capsule types, to this mode of killing by neutrophil proteases.
Ultimately, we possibly identify a novel component of pneumococcal pathogenesis involved
in evading one of the most crucial leukocytes involved in pneumococcal clearance.
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CHAPTER II
PNEUMOCOCCAL ISOLATES DISPLAY A VARIABLE RANGE OF SENSITIVITY TO
NEUTROPHIL GRANULES
The initial focus of this research was to determine the relative sensitivity of
pneumococcal laboratory strains and isolates to neutrophil granules – a finding that had not yet
been reported in the literature. To do this, we established a general protocol in which
pneumococci were exposed to granules extracted from human neutrophils. This protocol was
mostly adapted from the protocol of Standish and Weiser, described above. We then compared
the survival of the bacteria exposed to the granules to untreated controls to calculate the percent
survival of each strain. This process involved many steps, which are described in detail below.
One of the first facets of pneumococcal sensitivity to neutrophils studied was whether the
site of isolation (colonization versus invasive disease) impacted resistance. It possible that
invasive pneumococci are able to evade this mechanism of killing better than isolates restricted
to nasopharyngeal colonization, which may not have the tools to resist neutrophil killing. To
further characterize this aspect of pneumococcal infection, both invasive isolates and
colonization isolates were obtained for this sensitivity assay.
Methods
Bacterial Strains and Culture Conditions
Pneumococcal invasive isolates (ABC isolates), isolated from either the blood or cerebral
spinal fluid (CSF) of patients with systemic pneumococcal disease, were received from the CDC
7

ABC isolate bank. Table 2.1 provides data on these invasive isolates. Carriage isolates (SPN
isolates), isolated from the nasopharynx of asymptomatic patients, were received from our
collaborator, Dr. Jason Rosch at St. Jude Children’s Hospital. Table 2.2 provides data on the
SPN isolates.
Table 2.1
Isolate #

Data on the invasive (ABC) isolates
Site of
Isolation

Patient Age
(years)

Patient
Survived?

Known
Antibiotic
Resistance
1
Blood
10
Y
23B
None
2
Blood
48
N
12F
None
3
Blood
5
Y
23A
None
4
Blood
4
Y
15A
Tetracycline,
Erythromycin
5
Blood
17
Y
19A
Tetracycline
6
Blood
6
Y
06C
None
7
Blood
10
Y
16F
None
8
Blood
37
Y
35B
None
9
Blood
3
Y
06C
Erythromycin
10
Blood
27
Y
18C
None
11
Blood
12
Y
23F
None
12
CSF
25
Y
06B
None
13
Blood
10
Y
19A
None
14
Blood
8
Y
15B
None
15
Blood
37
Y
12F
None
16
Blood
25
N
15C
None
17
Blood
61
Y
19F
None
18
Blood
14
Y
12F
None
19
Blood
37
Y
06C
None
20
Blood
1
Y
15B
None
21
Blood
33
Y
3
None
22
Blood
6
Y
06C
None
23
Blood
9
N
06A
Erythromycin
Table 1 provides known data on all 23 of the invasive (ABC) isolates used provided by the CDC.
Data provided includes the tissue the isolates were extracted from (blood or cerebral spinal
fluid), the age of the patients the isolates were extracted from (in years), if the patients survived
(yes or no), the capsular serotype of the isolates, and what antibiotics the isolates have known
resistance to.
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Serotype

Table 2.2

Data on the carriage (SPN) isolates
Isolate #

Site of Isolation

Known Antibiotic
Resistance
1
Nasopharynx
Erythromycin
2
Nasopharynx
None
3
Nasopharynx
Streptomycin
4
Nasopharynx
Tetracycline, Erythromycin
5
Nasopharynx
Tetracycline
6
Nasopharynx
None
7
Nasopharynx
None
9
Nasopharynx
None
11
Nasopharynx
None
12
Nasopharynx
None
13
Nasopharynx
None
14
Nasopharynx
Erythromycin
15
Nasopharynx
None
31
Nasopharynx
None
Table 2.2 provides known data on all 14 carriage (SPN) isolates used. Data provided includes the
tissue the isolates were extracted from and what antibiotics the isolates have known resistance to.
Each strain was first cultured on tryptic soy agar (TSA) plates supplemented with 5%
sheep’s blood (blood agar). From the blood agar plates, pneumococcal broth cultures were
inoculated using a sterile loop. These cultures were grown in either casitone plus yeast extract
(C+Y) medium or Todd Hewitt plus yeast extract (THY) medium in a 37º C water bath without
agitation until they reached an OD600 of approximately 0.5. Freezer stock cultures were made by
supplementing broth cultures with 20% glycerol. Stock cultures were stored at -80ºC. To make
aliquots of broth cultures, bacterial cultures at 0.5 OD were centrifuged at 13,000 rpm for ten
minutes at 4ºC. The supernatant above bacterial pellets was vacuumed off and pellets were
resuspended in freezing media (C+Y or THY containing 20% glycerol). 100 l aliquots were
dispensed in 1.5 ml microcentrifuge tubes and stored at -80ºC for at least 24 hours.
To find the concentration of aliquots, they were thawed on ice, vortexed, then serially
diluted in 1x phosphate-buffered saline (PBS) and plated on blood agar plates for quantitation.
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Typically, two 10-2 dilutions were done followed by two 10-1 dilutions, each of which were
plated as duplicate 10 l streaks on blood agar. These plates were incubated overnight in a 5%
CO2 incubator at 37ºC. Colony forming unit (CFU) counts were counted the next day and the
average was used to calculate the concentration in CFUs/ml. Most aliquots ranged in
concentrations from 2 x 108 to 2 x 109 CFUs/ml.
Neutrophil Isolation and Degranulation
Human blood was extracted from a healthy donor, and neutrophils were isolated as
described by Axis Shield PolymorphprepTM protocol with some minor changes. Five ml of blood
was layered slowly over 5 ml of Polymorphprep solution in 15ml conical tubes. Tubes were
centrifuged at 500x g for 35 minutes at room temperature. This created a multi-layered solution
in the tubes where the plasma layer was on top of mononuclear cell (MC) layer, followed by the
polymorphonuclear leukocytes (PMNs), and the majority of the red blood cells on bottom
(Figure 2.1). Using a Pasteur pipette, the plasma and MC layers were vacuumed off of the PMN
layer. Then, the PMNs were collected and transferred to a new tube. PBS was mixed with the
PMNs, and the tubes were centrifuged at 400x g for 10 minutes. This step often did not produce
a solid pellet and left many cells still suspended in the supernatant. So, this step was repeated by
splitting the solution in half, adding more 1x PBS to the cells to wash them, and centrifuging
again at 400x g for 10 minutes. The second wash with PBS usually produced a solid pellet of
cells. The supernatant was vacuumed off of the pellets, and the pellets were both resuspended in
the same 5 ml of ammonium chloride lysis buffer, or red blood cell lysis buffer, to lyse the
remaining red blood cells in a 37ºC water bath for 5 minutes. Cells were then spun again at 400x
g for 10 minutes. The supernatant was removed, and the cells were resuspended in 10 ml of
RPMI 1640 + L-Glu + HEPES (media). The cells were centrifuged in the media by spinning at
10

1200 rpm for 5 minutes. Finally, the neutrophils were resuspended in 10 ml of media again to
obtain a concentration count. Ten l was loaded onto a hemocytometer to obtain an average of
the quadrant counts. The cells were centrifuged again at 1200 rpm for 5 minutes. They were
resuspended in a calculated amount of media to obtain a concentration of 2 x 107 cells/ml. This
concentration was then rechecked by a hemocytometer count.

Figure 2.1

Purification of PMNs using PolymorphprepTM

MC = mononuclear cells; PMNs = polymorphonuclear leukocytes. This illustration shows the
result of centrifuging blood over Polymorphprep solution. Picture on right shows an actual
separation in a 15 ml conical tube (taken from PolymorphprepTM Application Sheet).

Isolated neutrophils were degranulated as similarly described by Standish and Weiser.
Extracted neutrophils at 2 x 107 cells/ml were induced to degranulate by incubating with
cytochalasin B (cytB) (5 g/ml; Sigma-Aldrich) for 5 minutes at 37°C, followed by incubation
with fMLP (10-7 M; Sigma-Aldrich) for a further 30 minutes. Degranulated neutrophils were
centrifuged at 1200 rpm for 5 minutes. Granules were then collected from the supernatant and
transferred to a pre-chilled 5 ml microcentrifuge tube to mix the degranulate solution well. From
there, 110 l aliquots were aliquoted into pre-chilled 1.5 ml tubes, which were stored at -80°C
for pneumococcal killing assays.
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Degranulate Microbicidal Assay
Pneumococcal killing assays were also done as similarly described by Standish and
Weiser. Pneumococcal and degranulate aliquots were thawed on ice. Then, pneumococci were
diluted in RPMI 1640 + HEPES + L-Glu to 2.5 x 106 CFUs/ml, and 106 CFU/ml were incubated
with 20 l of degranulate in a 100 l reaction at 37°C for one hour. Reactions were diluted in ice
cold 1x PBS and plated on blood agar. Plates were incubated overnight in 5% CO2 at 37°C.
Colony counts were quantitated the next day to calculate concentrations post-exposure to
degranulate, and counts were compared to untreated control counts to determine percent survival.
Zero-hour controls were also made, but not subjected to the one-hour incubation, and plated on
blood agar to ensure ~106 CFUs/ml of bacteria were used each time.
Concentration counts of both control and experimental reactions were loaded into Prism
software for graphing and statistical analyses. The percent survival of pneumococci was
calculated by dividing the degranulate-exposed reaction concentration by the unexposed
concentration and multiplying by 100%. This data was also loaded into Prism, separate of the
concentration data. This entire experiment was done in triplicate for each strain to obtain
repeatable results. A two-tailed unpaired t-test was performed in Prism on the concentration data
between the control and experimental concentration counts for statistical analysis. An alpha
value of 0.05 was used, and P-values less than 0.05 designated strains that were significantly
killed by granules.
Results
First, the sensitivity of 23 invasive isolates to degranulate killing was assessed. To first
look at the concentration counts on all of these strains, we separated the data into four graphs to
better analyze the strains individually. In all of these following graphs on concentration data, a
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minimum of 104 was used for the y-axis since no counts fell below this concentration. Figure 2.2
displays the killing of the first six invasive isolates by showing the concentrations of the exposed
concentrations compared to the control unexposed concentrations. Though the concentration
counts provide the raw data, graphing the percent survival of each strain is a more succinct
format to analyze the sensitivity of all of these isolates. Again, the percent survival was
calculated by dividing the experimental concentration by the control concentration and
multiplying by 100%. This was done for each replicate for each strain; so, the average percent
survival for all 23 invasive isolates is shown in Figure 2.6. Of the first six invasive isolates,
ABC2 and ABC5 were killed significantly by degranulate with p-values of 0.0313 and 0.0159,
respectively. ABC2 was the most susceptible of these with a survival of 23.4%, and ABC1 was
the most resistant demonstrating a survival of 59.8%.

Figure 2.2

Sensitivity to granule-mediated killing of first six invasive isolates

Roughly 106 pneumococci per ml were exposed to granules extracted from human neutrophils
for one hour at 37ºC. Concentration counts were quantitated and compared to concentration
counts of the same concentration of pneumococci, that were not exposed to granules. Data shown
are the means ± standard deviation (SD) for control and experimental (+) counts of six invasive
isolates – ABC1 (blue), ABC2 (red), ABC3 (green), ABC4 (purple), ABC5 (orange), and ABC6
(teal). Asterisks (*) indicate strains significantly killed by degranulate.
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Figure 2.3 shows the concentrations of ABC 7-12 isolates. Of these six isolates only
ABC12 was significantly killed by degranulate (p = 0.0035). ABC9 was the most susceptible
isolate, however, at 12% survival, while ABC10 was the most resistant isolate at 75.7% survival.

Figure 2.3

Sensitivity to granule-mediated killing of ABC 7-12 isolates

Data shown are the means ± SD for control and experimental counts of six invasive isolates.
Shown are ABC7 (blue), ABC8 (red), ABC9 (green), ABC10 (purple), ABC11 (orange), and
ABC12 (teal). Asterisks (*) indicate strains significantly killed by degranulate.

The concentrations of ABC 13-18 isolates are displayed in Figure 2.4. The majority of
these isolates displayed higher susceptibility rates compared to the first 12 isolates with ABC15
being the most resistant and the only one of these six isolates not being significantly killed (p =
0.0788). ABC13 was highly susceptible at 6.6% survival (p = 0.0014). ABC14 was also a
significantly sensitive invasive isolate at 5.1% survival (p < 0.0001). ABC16 displayed a
significantly sensitive survival rate of 17% (p = 0.0011). ABC17 was the most sensitive of all of
the isolates tested at 4.9% survival (p = 0.026). Finally, ABC18 exhibited an 8.9% survival rate
(p = 0.0042).
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Figure 2.4

Sensitivity to granule-mediated killing of ABC 13-18 isolates

Data shown are the means ± SD for control and experimental counts of six invasive isolates.
Shown are ABC13 (blue), ABC14 (red), ABC15 (green), ABC16 (purple), ABC17 (orange), and
ABC18 (teal). Asterisks (*) indicate strains significantly killed by degranulate.

For the final invasive isolates, concentration data can be found in Figure 2.5. The
majority of these final invasive isolates were also significantly killed by degranulate, with
ABC23 being the most resistant invasive isolate at 90.7% survival and the only one of the final
five invasive isolates to not be significantly killed by degranulate (p = 0.1751). ABC19 displayed
a survival rate of 20.1% (p = 0.0059). ABC20 was the most sensitive of the final invasive
isolates at 16.2% survival (p = 0.0104). ABC21 and ABC22 showed similar survival rates of
31.8% (p = 0.0004) and 33% (p = 0.0108), respectively.
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Figure 2.5

Sensitivity to granule-mediated killing of final five invasive isolates

Data shown are the means ± SD for control and experimental counts of the last five invasive
isolates. Shown are ABC19 (blue), ABC20 (red), ABC21 (green), ABC22 (purple), and ABC23
(orange). Asterisks (*) indicate strains significantly killed by degranulate.

The average percent survival of all 23 isolates is 35.41% and the median is 33%. Twelve
(52.2%) of these isolates had survival rates lower than the average and eleven (47.8%) had rates
higher than the average. Twelve (52.2%) of these isolates were significantly killed by
degranulate compared to their unexposed controls. ABC 7, 10, and 23 were the most resistant to
neutrophil granules, while ABC 13, 14, and 17 were the most susceptible isolates.
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Figure 2.6

Sensitivity of all 23 invasive isolates to degranulate killing by human neutrophils.

Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all 23 invasive isolates. Asterisks (*) indicate strains
significantly killed by degranulate.

Once the sensitivity of the 23 invasive isolates to degranulate was assessed, we tested the
sensitivity of 14 carriage isolates. Like the invasive isolates, the sensitivity was assessed by
looking at the concentration counts of exposed bacteria compared to unexposed bacteria and the
percent survivals of all 14 isolates (Figure 2.10). Figure 2.7 shows the concentrations of the first
six SPN isolates. Of the first six carriage isolates, strains 1 (p = 0.0108), 2 (p = 0.0034), 3 (p =
0.0023), and 6 (p = 0.0261) were significantly killed by degranulate. SPN2 was the most
sensitive of the first six isolates at 23% survival. SPN5 was the most resistant of all of the
clinical isolates and the only one that showed a survival rate above 100% at 127.9% survival.
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Figure 2.7

Sensitivity to granule-mediated killing of first six carriage isolates

Data shown are the means ± SD for control and experimental counts of six carriage isolates –
SPN1 (blue), SPN2 (red), SPN3 (green), SPN4 (purple), SPN5 (orange), and SPN6 (teal).
Asterisks (*) indicate strains significantly killed by degranulate.

Next, the degranulate killing assay was done on five more SPN isolates (Figure 2.8).
Three of the next five carriage isolates were significantly killed by degranulate – SPN7 at 54.9%
survival (p = 0.0139), SPN9 at 55.1% survival (p = 0.0294), and SPN13 at 83.3% survival (p =
0.0423). SPN11 was the most resistant of these five isolates and the second most resistant
clinical isolate at 94.8%.
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Figure 2.8

Sensitivity to granule-mediated killing of five carriage isolates

Data shown are the means ± SD for control and experimental counts of five carriage isolates.
Shown are SPN7 (blue), SPN9 (red), SPN11 (green), SPN12 (purple), and SPN13 (orange).
Asterisks (*) indicate strains significantly killed by degranulate.

The final three carriage isolates and their concentration counts after degranulate exposure
are displayed in Figure 2.9. SPN15 was the only isolate not significantly killed by degranulate (p
= 0.1512). However, SPN14 was the most resistant isolate of these three at 68.3% survival, even
though it was significantly killed compared to its untreated control (p = 0.0137). SPN31 was
significantly killed and was the most susceptible of these three at 40.8% (p = 0.0036).
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Figure 2.9

Sensitivity to granule-mediated killing of final three carriage isolates

Data shown are the means ± SD for control and experimental counts of three carriage isolates.
Shown are SPN14 (blue), SPN15 (red), and SPN31 (green). Asterisks (*) indicate strains
significantly killed by degranulate.

The average percent survival of all of the carriage isolates was actually significantly
higher than the invasive isolates at 64.55% (p = 0.0021) (Figure 2.11). The median of the
carriage isolates’ survivals was calculated to be 63.55%. Half of the carriage isolates’ percent
survivals fell under the average and half were above the average. Nine (64.3%) of the 14 carriage
isolates were significantly killed by neutrophil degranulate. Collectively, the average survival of
all of the clinical isolates tested was 46.4% while the median was 40.77%. Nineteen (51.35%) of
the 37 isolates tested were significantly inhibited by granule-mediated killing.
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Figure 2.10

Sensitivity of all 14 carriage isolates to granule-mediated killing by human
neutrophils

Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all 14 carriage isolates. Asterisks (*) indicate strains
significantly killed by degranulate.

Figure 2.11

Average sensitivity of invasive isolates and carriage isolates

The average sensitivities of invasive isolates and carriage isolates were assessed with an
unpaired two-tailed t test. Asterisk (*) indicates that a significant difference was found between
the average sensitivities of the two types of isolates.

21

Discussion
This study was important because it was the first one to be conducted that quantitated the
sensitivity of a panel of isolates to granule-mediated killing by human neutrophils. Two major
conclusions were drawn from the results of this study. First, resistance to this form of killing is
not exclusive only to strains originally isolated from invasive sites. Second, many isolates have
acquired a resistance factor or overexpress a virulence factor leading to resistance to degranulate.
As stated earlier, invasiveness of isolates was the first facet of pneumococcal isolates that
we wanted to investigate as possibly contributing to resistance. After testing the panel of 23
invasive isolates and finding only a few to display a highly resistant phenotype, we determined
that invasive-site isolation was not indicative of resistance against neutrophil granules. This
conclusion coupled with the outcome of a 35.41% average survival rate quickly undermined this
first theory. Then, we discovered that more carriage isolates displayed the highly resistant
phenotype and the average survival rate was 64.55% among carriage isolates, significantly
higher than that of the invasive isolates. Therefore, we ruled out the idea that invasiveness was
key to completely evading degradation by neutrophils during both colonization and during
disease.
While invasiveness was clearly not directly associated with resistance, the presence of
many highly resistant isolates led us to believe a factor must be involved. We hypothesized these
resistant isolates may have evolved a defense mechanism or are overexpressing a virulence
factor with an unknown function of protection from neutrophil granules.
Immediately, the capsule types of all of these isolates were investigated to determine
whether the capsule type or another characteristic of the capsule may be at play. We utilized data
provided by the CDC on the capsule types of all of the invasive isolates we used. Unfortunately,
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we did not have this data on the carriage isolates. One interesting finding was that our most
resistant invasive isolate ABC23 was of the capsule type 6A, the same capsule type Standish and
Weiser saw significant killing by degranulate. On the other hand, we did not see significant
killing and recovered 91% of the cells of this isolate after exposure to degranulate. In our panel
of 23 invasive isolates, four capsule types were represented by multiple isolates. Capsule type
06C was represented by ABC6, ABC19, and ABC22. The average survival of these three isolates
were strictly tight around 33%. However, we saw a few discrepancies in the other isolates that
represented the same capsule types. ABC2, ABC15, and ABC18 represented capsule type 12F.
The average percent survival of these were 23.4%, 35.6%, and 8.9%, respectively. These percent
survivals varied substantially more than the 06C isolates. Likewise, two isolates of capsule type
19A varied greatly in their percent survival. ABC5 had a 40.7% survival rate, whereas ABC13
only had a 6.6% survival rate. Finally, two type 15B isolates, ABC14 and ABC20, had a small
difference in their sensitivities to degranulate – 5.1% and 16.2% survival, respectively. This
disparity was not as substantial as the ones among type 12F and 19A isolates, but it also wasn’t
as close as the 06C isolates. These differences led us to believe capsule type, alone, does not
determine sensitivity to granule-mediated killing by neutrophils.
Another aspect of the capsule type that we investigated was whether resistance was
profound among capsule types infamous for causing invasive disease. Of the capsule types
notorious for invasive disease, especially in children, types 6A, 6B, and 19F were represented in
our panel of invasive isolates. Again, our type 6A isolate, ABC23, was highly resistant.
However, our type 6B isolate, ABC12, showed moderate sensitivity at 42.1%. Furthermore, our
type 19F isolate, ABC17, displayed heightened susceptibility at 4.9% survival. This is further
evidence that the capsule type does not factor extensively in the sensitivity to degranulate. We
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did not, however, completely discount the capsule in involvement to susceptibility or resistance.
Rather, we investigated if the presence of the capsule affected the sensitivity of pneumococci to
granule killing.
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CHAPTER III
ABSENCE OF PNEUMOCOCCAL CAPSULE MAY AFFECT SENSITIVITY TO
GRANULE-MEDIATED KILLING BY NEUTROPHILS
Analysis of the invasive isolates revealed that the capsule type alone was not predictive
of susceptibility to granules. However, this evidence required further investigation since the
capsule’s contribution to pneumococcal protection is multifactorial. For instance, the negative
surface charge of most pneumococci plays an extensive role in the bacteria’s abilities to evade
host defenses including the also negatively charged mucus and neutrophils (Nelson et al., 2007;
Li et al., 2013). Additionally, the absolute requirement for capsule as a sine qua non virulence
factor has recently been called into question.
Non-encapsulated Streptococcus pneumoniae (NESp) isolates have been steadily
increasing in the population; and they are being maintained in the population, even at low levels,
despite lacking this key virulence factor (Ing et al., 2012; Park et al., 2014). These NESp isolates
have occurred due to either mutated capsule polysaccharide synthesis (cps) genes leading to no
capsule production (Hathaway et al., 2004), or other genes substituted in place of the cps genes
(Keller et al., 2016). In the cases of the latter, three genes have so far been found to replace those
of cps locus: aliC, aliD, and pneumococcal surface protein K (pspK). Three different null
capsule clades (NCCs) divide this group of NESp isolates based on which gene(s) can be found
at the cps locus. NCC1 isolates are pspK+, but aliC- and aliD-. NCC2 isolates are aliC+ and
aliD+, but pspK-. And NCC3 isolates are only aliD+.
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We investigated the granule-sensitivity of many unencapsulated isolates, including
isolates of the three different NCCs, to determine if the absence of the capsule impacted
resistance to granule-mediated killing, and if the specific gene in place of the cps locus
determined susceptibility to neutrophil granules.
Methods
Bacterial Strains and Culture Conditions
Non-encapsulated Streptococcus pneumoniae isolates and their mutants were graciously
gifted to us by Larry McDaniel at the University of Mississippi Medical Center. Table 3.1
provides information on all of the NESp isolates and their mutants. All NESp isolates were
carriage isolates isolated from the nasopharynx of colonized individuals. Mutants of MNZ41
include an aliC and aliD double knockout mutant (JLB01) and cbpAC knockout (JLB10). Two
mutants of MNZ67 were received – a pspK knockout (LEK05) and a potD knockout (PIP01).
Finally, LEK08 is an aliC and aliD double knockout of MNZ85. Wildtype TIGR 4 and a capsule
knock-out mutant of TIGR4 (T4R) were also used in this study and displayed in Table 3.1.
Culture conditions were carried out in the same manner as with the ABC and SPN isolates. One
interesting aspect of the NESp isolates to be noted was that flocculent growth was observed
throughout cultures in C+Y. This type of growth differed from the uniform growth of the
encapsulated isolates, and it most likely was an occurrence of the absence of the capsule.
However, vigorous pipetting was used to disperse bacteria during growth phase. This helped
speed up the exponential growth phase. Another distinctive aspect of NESp isolate growth was
the small size of their colonies, compared to encapsulated isolates.
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Table 3.1

Data on NESp isolates, their mutants, TIGR4, and its capsule knockout mutant
T4R

Strain Name

Type of Strain

Site of Isolation
(only for
isolates)

Known
Antibiotic
Resistance

Nasopharynx

Parental
Strain and
Gene Deleted
(only for
mutants)
N/A

MNZ11

Isolate

MNZ41

Isolate

Nasopharynx

N/A

None

MNZ67

Isolate

Nasopharynx

N/A

None

MNZ85

Isolate

Nasopharynx

N/A

None

NCC1A

Isolate

Nasopharynx

N/A

None

NCC1B

Isolate

Nasopharynx

N/A

None

NCC1D

Isolate

Nasopharynx

N/A

None

NCC1E

Isolate

Nasopharynx

N/A

None

NCC1F

Isolate

Nasopharynx

N/A

None

NCC1G

Isolate

Nasopharynx

N/A

None

NCC1H

Isolate

Nasopharynx

N/A

None

NCC2A

Isolate

Nasopharynx

N/A

None

NCC2B

Isolate

Nasopharynx

N/A

None
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None

Table 3.1 (continued)
Strain Name

Type of Strain

Site of Isolation
(only for
isolates)

Known
Antibiotic
Resistance

Nasopharynx

Parental
Strain and
Gene Deleted
(only for
mutants)
N/A

NCC2C

Isolate

NCC2D

Isolate

Nasopharynx

N/A

None

NCC2E

Isolate

Nasopharynx

N/A

None

NCC2F

Isolate

Nasopharynx

N/A

None

NCC3A

Isolate

Nasopharynx

N/A

None

NCC3B

Isolate

Nasopharynx

N/A

None

JLB01

Mutant

N/A

MNZ41; aliC

None

None

and aliD
JLB10

Mutant

N/A

MNZ41;

None

cbpAC
LEK05

Mutant

N/A

MNZ67; pspK

None

LEK08

Mutant

N/A

MNZ85; aliC

None

and aliD
PIP01

Mutant

N/A

MNZ67; potD

None

TIGR4

Laboratory

N/A

N/A

None

N/A

TIGR4; cps

Chloramphenicol

Strain
T4R

Mutant

genes
Table 3.1 provides data on all 19 NESp isolates used, five of their mutants, TIGR4, and T4R.
Data provided for each strain includes type of strain (isolate, mutant, or laboratory strain), the
site of isolation (only for isolates), the parental strain and gene deleted only in mutants, and what
antibiotics the strains have known resistance to.
Degranulate Microbicidal Assay
Killing assays were performed as described above for invasive and encapsulated carriage
isolates (Chapter II). Again, CFU counts were quantitated to determine concentrations post28

exposure to degranulate and compared to untreated controls. Concentration data along with
percent survival of each strain were graphed and analyzed using Prism software. Two-tailed ttests were performed on control and exposed concentrations to determine if strains were
significantly killed. An alpha value of 0.05 was deemed significant. The sensitivities of mutants
of some of the NESp isolates were also tested and the differences in survivals compared to
wildtypes assessed via a t-test. Additionally, a t-test was carried out on the survival of T4
compared to T4R to determine significance.
Results
First, the sensitivity of four NESp isolates to degranulate was assessed. Figure 3.1
displays the sensitivity of the four unencapsulated isolates, while the percent survival of the
NESp isolates is shown in Figure 3.2. Three of the four isolates exhibited the highly resistant
phenotype with MNZ85 displaying the highest resistance at 146.6% survival. One of these
isolates, MNZ67 was significantly killed by degranulate with only 33.7% survival (p = 0.0113).
The average percent survival of these four isolates was 109% while the median was 110.9%.

Figure 3.1

Sensitivity to granule-mediated killing of first four unencapsulated isolates

Roughly 106 pneumococci per ml were exposed to granules extracted from human neutrophils
for one hour at 37ºC. Concentration counts were quantitated and compared to concentration
counts of the same concentration of pneumococci, that were not exposed to granules. Data shown
are the means ± standard deviation (SD) for control and experimental (+) counts of four
unencapsulated isolates – MNZ41 (blue), MNZ11 (orange), MNZ85 (purple), and MNZ67
(green).
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Figure 3.2

Sensitivity of the first 4 NESp isolates to granule-mediated killing

Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of ten unencapsulated isolates. Asterisk (*) indicates the one strain
significantly killed by degranulate.

After analyzing this data on the first four unencapsulated isolates and finding that 75% of
them displayed the extremely resistant phenotype, it was theorized that the absence of the
capsule may actually reduce pneumococcal susceptibility to granule-mediated killing by
neutrophils. We speculated that without a capsule, these pneumococci may be upregulating or
displaying surface proteins with the ability to combat the granules. However, we needed to test
the sensitivity of a larger panel of NESp isolates and then compare the comprehensive data to the
encapsulated isolates before this can be determined. In order to further characterize the
sensitivity of NESp isolates, we were granted 15 NCC isolates from Larry McDaniel.
The 15 NCC isolates underwent exposure to degranulate via our microbicidal assay.
Exposed concentrations were again compared to control unexposed concentrations to
characterize percent survival. Percent survival of these 15 isolates is displayed in Figure 3.6.
Figure 3.3 shows the concentration data of the first five NCC isolates. Only the most resistant of
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these isolates NCC1D was not significantly killed by degranulate at 97.8% survival (p = 0.7728).
NCC1A was the most sensitive of these isolates at 46.2% survival (p = 0.0021). The other three
isolates displayed intermediate sensitivity – NCC1B at 53.5% (p = 0.0467), NCC1E at 73.6%
survival (p = 0.0159), and NCC1F at 77.4% survival (p = 0.0036) – but were all significantly
inhibited by granules.

Figure 3.3

Sensitivity to granule-mediated killing of first five NCC isolates

Data shown are the means ± SD for control and experimental counts of the first five NCC
isolates. Shown are NCC1A (blue), NCC1B (red), NCC1D (green), NCC1E (purple), and
NCC1F (orange). Asterisks (*) indicate strains significantly killed by degranulate.

Five more NCC isolates were exposed to degranulate and their concentrations are
indicated in Figure 3.4. NCC1H was the most sensitive of these isolates at 10.8% survival (p =
0.0009) while NCC2C was the most resistant at 55.6% survival, even though it was also
significantly killed (p = 0.0277). NCC2B was also significantly killed at 21.2% survival (p =
0.0002).
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Figure 3.4

Sensitivity to granule-mediated killing of five more NCC isolates

Data shown are the means ± SD for control and experimental counts of five NCC isolates.
Shown are NCC1G (blue), NCC1H (red), NCC2A (green), NCC2B (purple), and NCC2C
(orange). Asterisks (*) indicate strains significantly killed by degranulate.

The final five NCC isolates and their concentration data from degranulate killing assays
are shown in Figure 3.5. NCC2F was the most sensitive and the only isolate of this panel
significantly killed by degranulate at 38.2% survival (p = 0.0017). NCC3B was the most resistant
of these isolates at 93.7% survival.

Figure 3.5

Sensitivity to granule-mediated killing of last five NCC isolates

Data shown are the means ± SD for control and experimental counts of five NCC isolates.
Shown are NCC2D (blue), NCC2E (red), NCC2F (green), NCC3A (purple), and NCC3B
(orange). Asterisk (*) indicates the strain significantly killed by degranulate.
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The average percent survival among the NCC isolates was 55% and the median was
55.6% survival. Eight (53.3%) of the 15 NCC isolates were significantly killed by degranulate.
NCC1D was the most resistant NCC isolate at 97.8% survival. NCC1H was the most susceptible
NCC isolate at 10.8% survival. These data correlated more with the results from the encapsulated
isolates than the first panel of NESp isolates.

Figure 3.6

Percent survivals of all NCC isolates to granule-mediated killing by neutrophils

Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all 15 NCC isolates. Asterisks (*) indicate strains significantly
killed by degranulate.

After analyzing the NCC isolates, it was more apparent that the first panel of
unencapsulated isolates were improbably more resistant than the rest of the isolates tested, given
that it was a much smaller panel. The average of all of the unencapsulated isolates was calculated
to be 64.7%, and the median was calculated to be 57%. The survival of all of the unencapsulated
isolates was slightly higher than that of the carriage isolates but significantly higher than that of
the combined survival of the invasive and carriage encapsulated isolates, which averaged only
46.4% survival (p = 0.048) (Figure 3.7). Collectively, nine (47.4%) of the 19 unencapsulated
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isolates were significantly killed by neutrophil degranulate. However, this percentage of
significantly killed NESp isolates was slightly lower than that of the percentage of significantly
killed encapsulated isolates (51.35%).

Figure 3.7

Average sensitivity of encapsulated isolates and unencapsulated isolates

The average sensitivities of encapsulated isolates and unencapsulated isolates were assessed with
an unpaired two-tailed t test. Asterisk (*) indicates that a significant difference was found
between the average sensitivities of the two types of isolates.

In addition to all of the unencapsulated isolates’ sensitivities to the degranulate
microbicidal assay, we investigated the killing of a wildtype pneumococcal strain TIGR4 and its
capsule knock-out mutant T4R to access the effect the absence of the capsule has on degranulate
sensitivity. The concentrations of these two strains post-exposure to degranulate and their
untreated controls are shown in Figure 3.8, and the percent survivals are displayed in Figure 3.9.
These concentrations indicated that TIGR4 was significantly killed with an average survival rate
of 40.6% (p < 0.0001). T4R also exhibited significant susceptibility and an almost equal survival
rate to TIGR4 at 40% (p = 0.0006). It was evident from the concentration data that there was no
difference between survival of these two strains. This was confirmed by a t-test (p = .9416).
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Figure 3.8

Sensitivity to granule-mediated killing of TIGR4 and T4R

Data shown are the means ± standard deviation (SD) for control and experimental counts of
TIGR4 (blue) and its capsule knock-out mutant T4R (red). Asterisks (*) indicate strains
significantly killed by degranulate.

Figure 3.9

Percent survival of TIGR4 and T4R to granule-mediated killing by neutrophils

Percent survival of each strain was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all TIGR4 and T4R.

Next, we investigated the role of the genes in place of the cps locus and if any of them
affected sensitivity of unencapsulated pneumococci to granule-mediated killing. The mutants of
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NESp isolates were exposed to neutrophil degranulate, and their concentration data is shown in
Figure 3.10. Most of these mutants were extremely resistant except for PIP10 which was
significantly killed at 36% survival (p = 0.0008). JLB 10 was the most resistant mutant at
158.7% survival.

Figure 3.10

Sensitivity to granule-mediated killing of six mutants of unencapsulated isolates

Data shown are the means ± SD for control and experimental counts of six mutants of NESp
isolates. Shown are JLB01 (blue), JLB10 (red), LEK08 (green), LEK05 (orange), and PIP01
(teal). Asterisk (*) indicates the strain significantly killed by degranulate.

Figure 3.11 displays the percent survival of all of these mutants to their wildtype NESp
isolates. The only significant difference between wildtype and mutant survival was found
between the wildtype MNZ67 and its pspK knockout LEK05 (p = 0.0025). LEK05 was found to
be significantly more resistant than its wildtype. The survival of the potD knockout of MNZ67,
on the other hand, was not found to be significantly different than the wildtype. The aliC and
aliD double mutants of MNZ41 and MNZ85 were both found to be more sensitive than the
wildtypes, but not significantly.
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Figure 3.11

Percent survivals of all NESp wildtypes versus their mutants

Data shown are the means ± SD for the percent survival of four NESp isolates and their mutants.
Asterisk (*) indicates the only significant difference in percent survivals of wildtype and mutant.

The factor of which gene was in place of the cps locus was also assessed in the NCC
isolates. NCC1 isolates averaged a percent survival of 57.2%. NCC2 isolates averaged a survival
of 43%. NCC3 isolates averaged a survival of 83.6%. While the two NCC3 isolates were more
resistant than the other two types of isolates, a one-way ANOVA test determined that a
significant difference was not found among the three different clades of isolates (Figure 3.12).

Figure 3.12

Average survival of NCC1, NCC2, and NCC3 isolates

The average sensitivities of all three clades of NCC isolates were assessed with one-way
ANOVA. No significant difference was found among the three clades of isolates.
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Discussion
This study was important as it further elaborates on the sensitivity of pneumococcal
isolates to granule-mediated killing by human neutrophils. This is also the first study to
investigate the sensitivity of a panel of unencapsulated isolates to granule-mediated killing. The
conversation of the rising prevalence of NESp isolates is beginning to escalate as more NESp
isolates are isolated. Keller et al. (2016) predicted that these increases can be attributed to the
introduction of the pneumococcal conjugate vaccines, which have led to positive selection of
unencapsulated pneumococci, and a rise in awareness and better techniques for typing collected
samples. In the conversations of rising NESp isolate prevalence are multiple studies on the
resistance of these isolates to antibiotics (Sa-Leao et al., 2008, Sánchez-Tatay et al., 2008).
However, resistance of unencapsulated Streptococcus pneumoniae to granule-mediated
inhibition by human neutrophils is not been assessed prior to our studies.
We concluded in this study that NESp isolates have a minor significant advantage over
encapsulated isolates when it comes to resistance to this method of killing by neutrophils.
Furthermore, focusing more on the null capsule clades, it appears there is not a major difference
among the three NCC groups. The NCC1 (pspK+) and NCC2 (aliC+ and aliD+) isolates varied
greatly in their range of sensitivities to degranulate. Interestingly, both of our NCC3 (only aliD+)
isolates were of the highly resistant phenotype. Testing of more NCC3 isolates in future studies
would better characterize if the substitution of only aliD at the cps locus has an effect on
susceptibility. From our data on NCC1 and NCC2 isolates, it appears pspK and aliC do not have
effects on sensitivity, alone. However, the combination of any of these three genes substituted at
the cps locus could be further expanded on in future studies. Conflicting results were reported
from data on the mutants of NESp isolates, though, compared to the NCC isolates. The pspK
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mutant was significantly more resistant than its wildtypes. This pspK data contradicts the data on
NCC isolates. The only pspK+ isolates (NCC1) were slightly more resistant than NCC2 isolates
but more sensitive than NCC3 isolates. Again, testing of more NCC3 isolates could help
establish the role of pspK in susceptibility to granule-mediated killing by neutrophils.
Data on the survival of TIGR4 and its capsule knock-out mutant T4R provide evidence
that, at least for type 4, the capsule is not the sole factor involved in resistance to neutrophil
granules. This information combined with the capsule type information elaborated on in Chapter
II failed to strengthen an argument for capsule type having a significant impact on resistance of
pneumococci to granule-mediated killing by human neutrophils. However, the minor significant
difference between the survival of all NESp isolates and all encapsulated isolates provides
evidence to the contrary. Even within strains of the same capsule type, individual strains could
possess modifications to the capsule or differences in levels of capsule expression. As well,
strains of the same null capsule clade could have variable expression of surface factors involved
in resistance to granules. These are areas worthy of future investigation before capsule can be
completely ruled out as a contributing factor to resistance.
The increased survival shown by NESp isolates compared to encapsulated isolates may
provide evidence for a previously mentioned theory. We speculated that some pneumococcal
isolates may be upregulating or better-displaying components on their cell-surfaces due to the
differences in capsule type, amount, or presence. Therefore, investigation of known surface
virulence factors, to possibly identify a surface protein with an uncharacterized function in
protection from toxic neutrophil granules, is warranted.
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CHAPTER IV
POTENTIAL CONTRIBUTION OF PNEUMOCOCCAL CELL WALL-ASSOCIATED
PROTEASE HTRA AS A DEFENSE MECHANISM AGAINST NEUTROPHIL GRANULEMEDIATED KILLING
Our data on the sensitivity of the invasive and colonization isolates to granule-mediated
killing indicated that isolation of strains from invasive sites alone did not directly correlate to
granule resistance and that some strains express a factor that contributes to resistance.
Additionally, the capsule type alone does not appear to have a significant effect on susceptibility
of Streptococcus pneumoniae to neutrophil granular inhibition. Therefore, our third objective
was to identify a possible protective factor by reviewing the literature on already known
virulence factors.
Cell wall-localized aminopeptidase N (PepN) was reported as a target receptor for
neutrophil elastase (Nganje et al., 2019). By studying PepN in Streptococcus thermophilus,
Chavagnat et al. (1999) estimated PepN to cleave small peptides from the N-terminus. More
recently, though, S. pneumoniae PepN has been shown to inhibit production of IFN and TNF-
and release of cytolytic granules (Blevins et al., 2017). PepN belongs to the family of proteins
called non-classical surface proteins (NCSPs). While PepN appears to be a sensitivity factor in
this mechanism of neutrophil granule killing, we sought to determine whether other factors may
also contribute to resistance.
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Another protein in the NCSP family of proteins is a protease called HtrA (hightemperature requirement A). HtrA is a heat shock-induced, serine protease that was first defined
in E. coli, in which it is known as DegP or DO protease (Strauch et al., 1989). DegP was found
to be localized in the periplasm, where it functions in the degradation of misfolded proteins due
to elevated temperatures (Strauch et al., 1989; Seol et al., 1991). While protease activity is the
primary function of this protein at high temperatures, HtrA also functions as a chaperone protein
at lower temperatures (Spiess et al., 1999). In pneumococcus, HtrA is localized to the cell wall
(Sebert et al., 2002), and it primarily functions in the digestion of denatured proteins and
competence stimulating peptide (CSP) (Sebert et al., 2005; Cassone et al., 2012). In the latter
case, the proteolytic function is used to repress competence when the frequency of errors in the
folding of proteins is low (Stevens et al., 2011). HtrA and its homologues are pretty conserved
across bacterial species and mostly function in the responses to environmental stresses.
Because HtrA is vital to maintaining the normal metabolic functions of pneumococcus, it
has been characterized as a potential virulence factor. Pneumococcal HtrA is required for full
virulence in both pneumonia and bacteremia models, as D39 and TIGR4 wildtype strains were
significantly more lethal than HtrA-defecient mutants (Ibrahim et al., 2004). Similarly, fitness of
pneumococci during colonization appears to be dependent on HtrA as a htrA mutant showed
decreased fitness (Sebert et al., 2002).
Given this information on the roles of HtrA as a virulence factor in response to
environmental stresses, we theorized that HtrA may play a role in the response to neutrophil
granule toxicity. If this is the case, the sensitivity of pneumococcal isolates may depend on the
concentrations of the protease the bacteria secrete in order to counter neutrophil serine proteases.
It has already been shown that HtrA helps some Gram-negative bacteria escape phagocytes
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(Baumler et al., 1994; Elzer et al., 1996; Li el al., 1996). Therefore, this serine protease may be
the key to pneumococcal survival against the human neutrophil granular defense.
We hypothesized that pneumococcal HtrA protects the bacteria from the neutrophil’s
granular proteases. To test this theory, we made HtrA knockouts of both laboratory strains and
clinical isolates and tested the sensitivity of these strains to neutrophil granules. Additionally, we
expressed recombinant HtrA in an E. coli expression strain and subjected TIGR4 to both
degranulate and rHtrA. Finally, we performed quantitative real-time PCR on both highly
resistant and sensitive isolates to assess the levels of HtrA expression.
Methods
Construction of htrA mutants
The HtrA gene was deleted from wildtype strains and clinical isolates by overlap
extension PCR. In short, we amplified DNA flanking the htrA gene from the strains or isolates
using HtrA forward and reverse primers and conducted SOE and filling PCR to replace the gene
with an erythromycin (Erm) resistance gene cassette. Pneumococci were transformed with the
SOEing PCR product using standard methods. Briefly, cultures were grown to 0.6 OD600 in
competence media (C+Y supplemented with 0.4% BSA and 20% glucose) prior to being back
diluted (1:50) into competence media plus competence stimulating peptide 2 (CSP2). These
reactions incubated in a water bath at 37C for 13 minutes before addition of the HtrA KO
SOEing product (1µg). These reactions incubated a further two hours before being plated on 0.5
mg/ml Erm blood agar plates and grown overnight to select for htrA mutants. Transformants
were screened with Erm forward and reverse primers and grown in C+Y to an OD of 0.5, then
frozen in glycerol. Table 4.1 provides data on all of the primers used in this study. Table 4.2
provides data on the strains and mutants used in this study.
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Table 4.1

Primers
Primer Name
ERM Forward

Primer Sequence
GGA AAT AAG ACT TAG
AAG CAA AC
ERM Reverse
CCA AAT TTA CAA AAG
CGA CTC
HtrA Forward
AAT TCA AAC ATA TGG
AGG CAA A
HtrA Reverse
CTG TTG ATG AAG CAA
TCT CTT TGT
HtrA 2
CCA TGA TTC TAC ACT
AAC AC
HtrA 5
CAC CAT AAC TCA ACT
AAC TCA AAA AAG
HtrA RT Forward
TCG GAA GAT GGA CAA
GCT ATT T
HtrA RT Reverse
CCG ATA ACC TGC CCT
TGA ATA
HtrA-KO 1
GAA GGC GAA TGC TCT
ATC CA
HtrA-KO 2
GTT TGC TTC TAA GTC
TTA TTT CCC ATA TTT
GCC TCC ATA TG
HtrA-KO 3
GAG TCG CTT TTG TAA
ATT TGG TTG ACA TCT
ATG TAA AGA AAG C
HtrA-KO 4
AGC CTT ATT TCA GGC
TGT TG
Gyrase Forward
ATG AAC TCT TGG CTC
TGA TTG
Gyrase Reverse
CAA CTC TGT ACG GCG
CTT AT
Table 4.1 provides data on all of the primers used in this study. The data includes the primer
name and sequence.
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Table 4.2

Data on strains and mutants used in HtrA knockout experiments

Strain Name

Type of Strain

Parental Strain and
Gene Deleted (only
for mutants)

Known Antibiotic
Resistance

T4R

Laboratory Strain and
Mutant

TIGR4; cps genes

Chloramphenicol

JAT97

Mutant

T4R; htrA

Chloramphenicol,
Erythromycin

TIGR4

Laboratory Strain

N/A

None

JHJ1

Mutant

TIGR4; htrA

Erythromycin

JAT103

Mutant

TIGR4; htrA

Erythromycin

EF3030

Laboratory Strain

N/A

None

JHJ2

Mutant

EF3030; htrA

Erythromycin

ABC7

Isolate

N/A

None

JAT111

Mutant

ABC7; htrA

Erythromycin

ABC10

Isolate

N/A

None

JAT110

Mutant

ABC10; htrA

Erythromycin

Table 4.2 provides data on all of the laboratory strains, isolates, and mutants used in the HtrA
knockout studies. Data provided on each strain includes the type of strain (laboratory strain,
isolate, or mutant), the parental strain and gene deleted only for mutants, and what antibiotics the
strain have known resistance to.
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HtrA-deficient mutants and their wildtypes were tested for sensitivity to neutrophil
degranulate. These sensitivities were compared via the t-test to assess if htrA mutants were
significantly more susceptible to degranulate than the parental strains.
Construction of an E. coli expression strain and purification of HtrA
BL-21 E. coli cells were used to construct an HtrA expression strain. The cells were
incubated with pHtrA plasmid for 15 minutes on ice, then heat-shocked in a water bath for one
minute. 400 l of LB broth were added to the cells. The cells were then incubated on ice for five
minutes followed by 90 minutes of incubation in a shaking incubator at 37C. Then, 100 l of
transformed cells was plated on LB agar supplemented with 100 g/ml Ampicillin and incubated
overnight at 37C. Colonies were patched onto another LB Amp 100 plate for a master plate and
were also screened via PCR using HtrA forward primer 5 and reverse primer 2. Two positive
colonies were inoculated into LB broth supplemented with 100 g/ml Ampicillin from the
master plate and allowed to grow to an OD600 of 0.6. Freezer stock cultures were made from this
culture and stored at -80C. These stock cultures were labeled “HtrA100-1” and “HtrA100-2”.
To express HtrA, HtrA100-1 or HtrA100-2 was inoculated from the freezer stock into ten
ml of 100 g/ml Ampicillin LB broth, grown over night in a shaking incubator, back-diluted into
250 ml of LB Amp 100 broth, allowed to grow to 0.6 OD600, then induced with 1M IPTG and
allowed to grow overnight. Induced culture was pelleted in a Scorvall centrifuge at 5,000x g for
five minutes. The supernatant was decanted, and the pellet was resuspended in 30 ml of 1x PBS
for a wash – centrifuged at 5,000x g and supernatant decanted. The pellet was then resuspended
in 15 ml of bacterial protein extraction reagent (B-PER). The culture was then sonicated twice
before lysing with DNase and lysozyme. After rotating end-over-end at room temperature for 15
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minutes to lyse, the culture was spun again, this time at 13,000 rpm for five minutes. Lysate was
collected and stored at 4C until use in the nickel affinity chromatography experiment to purify
the rHtrA samples.
A volume of 3 ml of nickel resin was used in the chromatography to purify HtrA. The
nickel was washed in ultra-pure water before being charged by 16 ml of 1x charge buffer. Then,
10 ml of B-PER was used to equilibrate the nickel. The sample was then run over the nickel and
the flow through collected. Two washes with 1x 60mM imidazole wash buffer were run over the
nickel column to wash contaminating proteins out of the nickel. Elution buffer (1x) was used to
elute the protein, and half ml elutions were collected. SDS-PAGE was conducted on elutions,
sample flow through, and wash flow through. The nickel column was stripped with 1x strip
buffer before being regenerated for further use. A buffer exchange was conducted on elutions
with clean protein to suspend recombinant HtrA in HtrA storage buffer (25mM Tris-HCl,
300mM NaCl, 10% Glycerol).
HtrA Protection Assay
This assay was done similar to the standard degranulate microbicidal assay described in
Chapter II. 106 pneumococci/ml (checked by a zero-hour control) were incubated for one hour in
RPMI alone or supplemented with 20 ls of degranulate, 20 l of degranulate plus 20 l of 8
mg/ml rHtrA (in HtrA storage buffer), degranulate plus 8 mg/ml BSA, rHtrA, or BSA. Reactions
were diluted in 1x PBS and plated on 5% sheep’s BAPs, which were incubated overnight in 5%
CO2 at 37C. And colony counts were quantitated to assess the concentrations post-exposure to
degranulate and level of protection from HtrA.
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Quantitating levels of HtrA expression in resistant and sensitive isolates
To quantitate the levels of HtrA expression in isolates, RNA extractions and cDNA
synthesis were performed. Isolates were streaked on BAPs and grown overnight. From the
overnight cultures, C+Y broth cultures were inoculated and allowed to grow to 0.4 OD. Cultures
were then centrifuged and the supernatant removed. Pellets were resuspended in 400 l of 65C
hot acid phenol chloroform (HAPC). This reaction incubated at 65C for five minutes before
addition of 400 l of 65C NAES buffer. This reaction shook for one minute, incubated at 65C
for five minutes, then incubated on ice for two minutes. Then, the reactions were centrifuged for
two minutes at 13,000 rpm. The top aqueous layer was removed and collected in a new tube and
the HAPC and NAES treatment was repeated. After the second spin, the aqueous layers were
transferred to 5 ml microcentrifuge tubes. A tenth volume of DEPC-treated 3 M NaAC was
added to each tube followed by 2.5 volumes of 100% ethanol (EtOH). These reactions were
allowed to precipitate at -80C overnight.
The next day, reactions were thawed on ice and centrifuged at 15,000x g for 30 minutes.
Pellets were washed in one ml of 70% EtOH. After a 10-minute spin at 15,000x g, EtOH was
removed and the pellets air dried in a biosafety cabinet. Then, the RNA was isolated using the
Qiagen RNeasy kit. Pellets were resuspended in 100 l of RNase-free water before addition of
350 l of RLT buffer plus beta mercaptoethanol (-ME) and 250 l of 100% EtOH. Samples
were transferred to RNeasy mini spin columns in collection tubes and centrifuged at 10,000x g
for 30 seconds. Then, 350 l of RW1 buffer was added to the column, and the column was spun
again. DNase I incubation mix (10 l DNase stock solution plus 70 l RDD buffer per sample)
was prepared and all 80 l was added to the columns, which were incubated at RT for 15
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minutes. Then, 350 l of RW1 buffer was again added to the columns, and the columns were
centrifuged. Two washes were done with 500 l of RPE buffer before the columns were moved
to a 1.5 ml collection tube. 30 l of RNase-free water was added to the tubes to elute the RNA,
tubes were centrifuged, and the RNA samples were stored at -80C overnight.
Samples were thawed on ice and the RNA quantitated by a Qubit Fluorometer 2.0. RNA
broad range and DNA high sensitivity working solutions were prepared and distributed into
Qubit assay tubes. RNA and DNA standard tubes were prepared by adding 10 l of the
respective standard to 190 l of working solution. Assay tubes were prepared by adding 5 l of
RNA samples to 195 l of either RNA or DNA working solution. Standards were quantitated
prior to the assay tubes. Finally, assay tubes were quantitated, and a stock concentration was
calculated by the fluorometer.
To reduce residual contaminating DNA, samples underwent further RNA cleanup and
DNase treatment using the two-step rigorous DNase treatment protocol of the Ambion TURBO
DNA-freeTM kit by Invitrogen. A tenth volume of 10x TURBO DNaseTM Buffer was added to
RNA samples. Then, 1.5 l of TURBO DNaseTM enzyme was added to the samples, which
incubated in a 37C water bath for 30 minutes. Another 1.5 l of TURBO DNaseTM enzyme was
added to each sample, and samples were incubated an additional 30 minutes. Next, 0.2 volumes
of resuspended DNase Inactivation Reagent were added to each sample, which were then
incubated at RT for 5 minutes. Finally, samples were centrifuged at 10,000x g for 90 seconds
and most of the supernatants above the pellets was collected and transferred to new tubes. The
new RNA samples were brought to a total volume of 100 l with RNase-free water and the
Qiagen RNeasy RNA cleanup protocol was again used to further purify the RNA. Samples were
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again quantitated by the Qubit Fluorometer 2.0. Second readings usually indicated significantly
less DNA.
cDNA synthesis using the Maxima First Strand cDNA Synthesis Kit for RT-qPCR was
performed on the RNA samples. For each sample, 1 g of RNA template, 4 l of 5x reaction
mix, 2 l of Maxima enzyme mix, and enough nuclease-free water to fill to 20 l was mixed in a
sterile PCR tube. A no-RT reaction was done as well using the RNA template of the strain with
the most contaminating DNA in the RNA samples, and this sample underwent the same
treatment as the others but with no Maxima enzyme mix. In a thermocycler, the samples were
incubated at 25C for 10 minutes followed by incubation at 50C for 15 minutes. Reactions were
terminated at 85C for 5 minutes.
qPCR was performed on 50 ng of cDNA synthesized from cleaned RNA samples.
Luminaris Color HiGreen High Rox SYBR Green was used to perform qPCR on the four
samples targeting both HtrA and the housekeeping gene of Gyrase (gyrA). Each sample was run
in triplicate and in 20 l reactions in a 96-well plate. Negative controls consisted of no-RT
samples as well as no template controls. Reactions targeting gyrA and htrA used 0.6 l of RT
forward and reverse primers. Holding stage was conducted at 95C for 10 minutes. 40 cycles of
cycling stage were conducted at 95C for 15 seconds followed by 60C for one minute. Melt
curve stage was conducted once with the same parameters as cycling stage.
The delta cycle threshold (ct) of at least two qPCR runs of three isolates was calculated
by subtracting the mean ct of gyrA from the mean ct of htrA. The ct of two sensitive isolates
was calculated by subtracting the absolute value of the highly resistance isolate ct from the ct
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of the sensitive isolates. The fold change in expression of each sensitive isolate was calculated by
taking the power of 2 to the -ct.
Results
Construction of htrA mutants and their sensitivities to degranulate killing
HtrA knockout mutants were constructed from an array of wildtype pneumococci and
resistant pneumococcal isolates by overlap extension PCR followed by transformation of
SOEing PCR products. Preliminary work involved the deletion of htrA from the unencapsulated
lab strain T4R. JAT97 was the resulting mutant and the gel electrophoresis to confirm this knock
out can be seen in Figure 4.1. Survival counts are shown in Figure 4.2 while percent survivals are
displayed in Figure 4.3. When assessed in the standard microbicidal killing assay, T4R was
significantly killed at 40.93% (p = .0003). JAT97 was also significantly killed at 9.9% (p <
0.0001). JAT97 was significantly more sensitive to neutrophil granules than its wildtype T4R (p
= 0.0372).
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Figure 4.1

Electrophoresis gel of wildtype pneumococcal strains and their htrA knockouts

Ex Taq PCR screening was conducted on wildtype and mutant pneumococci using Erm forward
and reverse primers. Bands indicate presence of Erm cassette in place of htrA.

Figure 4.2

Survival of T4R and its htrA-deficient mutant JAT97 post-exposure to granules

Roughly 106 pneumococci per ml were exposed to granules extracted from human neutrophils
for one hour at 37ºC. Data shown are the means ± standard deviation (SD) for control and
experimental counts of T4R (blue) and JAT97 (red). Asterisks (*) indicate strains significantly
killed by degranulate.
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Figure 4.3

Percent survival of T4R and JAT97 to granule-mediated killing by neutrophils

Data shown are the means ± SD for the percent survival of T4R and JAT97. Asterisk (*)
indicates that JAT97 was significantly more susceptible to degranulate killing than the wildtype
T4R.

After the demonstration of increased susceptibility by the htrA mutant of T4R, we
wanted to ensure that this significant change in survival due to HtrA was not exclusive to just
one wildtype Streptococcus pneumoniae strain. Therefore, we deleted htrA from the
chromosomes of two other wildtype strains, TIGR4 and EF3030. Two mutants of TIGR4 were
created and were named JHJ1 and JAT103, and the gel electrophoresis screens to confirm the
knockouts can be seen in Figure 4.1. Additionally, htrA was deleted from the genome of EF3030
to create JHJ2, also confirmed in Figure 4.1. Survival counts for these wildtype and knockout
mutants are shown in Figure 4.4 while percent survivals are displayed in Figure 4.5. When
assessed in the microbicidal killing assay compared to its htrA-deficient mutants, TIGR4
displayed a survival rate of 17.3% (p < 0.0001). However, neither of the TIGR4 mutants were
killed like the wildtype. In fact, they were significantly more resistant than the wildtype. JHJ1
exhibited a survival rate of 97.8%, significantly more resistant than TIGR4 (p = 0.0078). JAT103
demonstrated an average survival of 119.84%, also significantly more resistant than the wildtype
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TIGR4 (p = 0.0015). EF3030 was significantly killed at 59% survival (p = 0.029). JHJ2 was also
significantly killed, displaying a survival rate of 3.57% (p = 0.0003). Interestingly, the EF3030

htrA mutant, JHJ2, was killed significantly more than the parental EF3030 (p = 0.0214), similar
to results seen with JAT97 and indicating that HtrA may be protective in this strain.

Figure 4.4

Survival of wildtype pneumococci and their htrA-deficient mutants to granules

Data shown are the means ± standard deviation (SD) for control and experimental counts of two
wildtype pneumococcal strains and their htrA mutants. Shown are T4 (blue), JHJ1 (red),
JAT103 (green), EF3030 (purple), and JHJ2 (orange). Asterisks (*) indicate strains significantly
killed by degranulate.
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Figure 4.5

Sensitivity of wildtype pneumococci and their htrA-deficient mutants

Data shown are the means ± SD for the percent survival of TIGR4, JHJ1, JAT103, EF3030, and
JHJ2. Asterisks (*) indicate significant differences in wildtype and mutant survivals.

The final study on sensitivities of wildtype versus htrA mutants to degranulate was done
with two of the most resistant invasive isolates. A knockout of ABC7 was created and named
JAT111, and a mutant of ABC10 was made and named JAT110. The confirmations of these
knockouts can be found in Figure 4.6. The survival counts are shown in Figure 4.7 while the
percent survivals are displayed in Figure 4.8. In this study, ABC7 exhibited an average survival
of 112%. JAT111 showed a survival of 66.94%. JAT111 is significantly more sensitive to
degranulate than ABC 7 (p = 0.0408). ABC10 demonstrated an average survival rate of 71.46%.
JAT110 was significantly killed at 65.7% (p = 0.0113). However, the difference in percent
survival between ABC10 and JAT110 was not significant (p = 0.676).
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Figure 4.6

Electrophoresis gel of wildtype pneumococcal isolates and their htrA knockouts

Ex Taq PCR screening was conducted on wildtype and mutant pneumococci using Erm forward
and reverse primers. Bands indicate presence of Erm cassette in place of htrA.

Figure 4.7

Concentrations of resistant invasive isolates and their htrA-deficient mutants postexposure to degranulate

Data shown are the means ± standard deviation (SD) for control and experimental counts of two
wildtype pneumococcal invasive isolates and their htrA mutants. Shown are ABC7 (blue),
JAT111 (red), ABC10 (green), and JAT110 (purple). Asterisk (*) indicates the strain
significantly killed by degranulate.
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Figure 4.8

Sensitivity of wildtype invasive isolates and their htrA-deficient mutants

Data shown are the means ± SD for the percent survival of ABC7, JAT111, ABC10, and
JAT110. Asterisk (*) indicates that a significant difference of survival was found between
wildtype and mutant.

E. coli expression strains and purification of HtrA
The pHtrA plasmid previously cloned into E. coli (TOP-10) was screened with primers
HtrA 2 and HtrA 5 to confirm the presence of the gene within the plasmid. The htrA gene was, in
fact, present within the plasmid, and the plasmid was used to transform BL-21 cells. After
transformation of the plasmid into E. coli (BL21), twelve colonies were selected and patched
onto another LB plate, and we screened the first nine colonies patched for pHtrA. Figure 4.9
displays the gel electrophoresis of the screened transformants. The first two transformants were
positive and were selected to grow and freeze for purification of HtrA. These two colonies were
labelled “HtrA 100-1” and “HtrA 100-2”.
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Figure 4.9

Gel electrophoresis of nine transformants from the transformation of pHtrA into
BL-21 E. coli

Nine transformants were screened with HtrA primers 2 and 5 and ran on a .8% agarose gel. All
transformants screened except for numbers 4 and 8 were positive for the HtrA plasmid. The first
two were selected to grow for purification of recombinant HtrA.

HtrA Protection
To determine if HtrA contributed to protection against neutrophil granules, S.
pneumoniae TIGR4 was exposed to degranulate in the presence or absence of rHtrA (8 mgs/ml).
BSA was used as a protein control in this assay to ensure that the neutrophil granules were not
simply overloaded with protein. The bacterial survival counts from this assay can be seen in
Figure 4.10 and the percent survivals in Figure 4.11. A zero-hour control was plated on blood,
and concentration counts revealed the correct concentration of bacteria was used. However, the
one-hour TIGR4 control displayed a lower concentration. Following one-hour incubation with
degranulate, TIGR4 CFUs decreased 97.9% (p = 0.0311). This was abrogated when TIGR4 was
exposed to degranulate in the presence of recombinant HtrA, actually resulting in a significant
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increase in bacterial growth of 1,048% (p = 0.0438) over TIGR4 incubated for one hour in the
absence of degranulate. The survival of HtrA-protected TIGR4 was also significantly higher than
that of unprotected TIGR4 exposed to granules (p = 0.0004). This effect did not seem to be
HtrA-specific since addition of BSA also substantially protected TIGR4 against degranulate,
though it did not result in the increase in growth seen with HtrA supplemented samples. TIGR4
was exposed to either HtrA or BSA alone to see if the proteins hindered TIGR4 growth, but no
such hinderance was found (data not shown).

Figure 4.10

Survival of TIGR4 exposed to granules and rHtrA or BSA

106 pneumococci per ml were exposed to granules extracted from human neutrophils and either
HtrA or BSA for one hour at 37ºC. Data shown are the means ± standard deviation (SD) for a
zero-hour control (blue), a one-hour control (red), a degranulate-exposed (green), and
degranulate-exposed and HtrA-protected (purple), and a degranulate-exposed and BSA-protected
(orange) TIGR4. Asterisks (*) indicate significant differences in CFUs.
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Figure 4.11

Percent survival of TIGR4 exposed to granules and HtrA or BSA

Data shown are the means ± SD for the percent survival of TIGR4 to degranulate and TIGR4
exposed to degranulate and HtrA or BSA. Asterisk (*) indicates a significant difference in
survival.

HtrA Expression
To evaluate the possible role of HtrA in resistance of isolates, htrA expression was
compared in two highly granule-susceptible isolates (ABC13 and ABC14) to expression in a
highly resistant isolate (ABC7). The fold changes of the two sensitive isolates compared to
ABC7 are shown in Figure 4.12. ABC13 displayed only 29.4% the level of htrA expression
ABC7 did, while ABC14 displayed 57.2% the level of htrA expression as ABC7.
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Figure 4.12

Expression of ABC13 and ABC14 compared to ABC7

qPCR was conducted on ABC7, ABC13, and ABC14 targeting htrA. ct was calculated for the
isolates 13 and 14 compared to ABC7 using mean cts of multiple runs. Shown are expression
levels of ABC13 (red) and ABC14 (green) related to ABC7 (blue).

Discussion
Much of our data indicates that HtrA may have a significant role in the resistance of
Streptococcus pneumoniae to granule-mediated defense by human neutrophils. The evidence to
this claim is found in the significant decrease in survival to degranulate by half of the htrA
mutants compared to the wildtypes, the increase of TIGR4 survival when protected by
recombinant HtrA purified from E. coli, and the lower expression levels of htrA in two extremely
susceptible isolates compared to a highly resistant isolate.
The experiments involving the HtrA-deficient mutants were encouraging as half of the
mutants were significantly more susceptible to degranulate than the wildtypes. Neither of the
TIGR4 mutants were more sensitive than the wildtype. In fact, they were both significantly more
resistant. On the other hand, the T4R mutant was significantly more susceptible than the
wildtype. But T4R itself is an unencapsulated mutant of TIGR4. This is quite interesting as
neither the loss of the capsule nor HtrA, alone, decreased the sensitivity of TIGR4. But the loss
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of both the capsule and HtrA extensively decreased sensitivity. The significant decrease in
survival when HtrA was deleted from EF3030 was promising, however, as it provided evidence
that another pneumococcal strain benefited from HtrA expression in the presence of neutrophil
granules. The testing of the two resistant invasive isolates and their mutants was also intriguing.
ABC7’s mutant was not significantly killed by degranulate compared to its control that was not
exposed to degranulate. But the survival of JAT111 was significantly lower than that of its
wildtype. On the other hand, ABC10’s mutant was significantly killed by degranulate compared
to its untreated control; but, the difference in survivals between JAT110 and ABC10 was not
significant. This provided conflicting results when taken as a whole and indicates strain-specific
contribution. ABC7 did appear to be much more resistant in the three trials with its mutant
compared to its testing with the panel of invasive isolates. Conversely, ABC10 appeared to be
quite more sensitive. These studies should be improved on in the future where more isolates of
different rates of susceptibility are tested, and tighter standard deviations are observed.
The HtrA protection data on TIGR4 is promising in that we see such substantial
protection. However, there are a few drawbacks to this assay. First, the purification of the protein
was not very clean as there were contaminating proteins in the elutions. While HtrA is the major
protein found in the elutions, it is concerning to see the presence of other proteins. Without a
clean purification of HtrA, one could speculate that protection may also be due in part by the
other proteins, or simply, the presence of other proteins distracts the proteases of the neutrophil
granules from targeting the bacteria. The latter case is something we speculated might be seen
when supplementing HtrA into the protection reactions. This is why we also ran protection
reactions with BSA. It was concerning to see such protection by the BSA. However, TIGR4
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survival from this protection was not as substantial as the protection seen by HtrA, nor was it
significant compared to degranulate alone exposed TIGR4 like the HtrA-protected TIGR4.
Another drawback in this assay was the fact that TIGR4 did not acclimate well in the
RPMI medium used for killing and protection assays. This was evident in the difference between
the zero-hour and one-hour controls. However, this difference between zero-hour controls and
one-hour controls was also seen across many of the wildtype strains and isolates tested and
resulted in a decrease in CFU after one-hour incubation. This medium was used, though, as it
was the best medium for extracting the azurophilic granules from the human neutrophils.
Besides, the medium didn’t seem to be a major factor as such a wide range of sensitivity was
observed across all of the strains tested, even with an incubation of only one hour.
To investigate if the granule-mediated killing or HtrA protection was time-sensitive, we
did run two-hour and three-hour reactions in the protection assay (data not shown). However,
controls and exposed TIGR4 were decreasing to nearly none by hour 2, and HtrA-protected
TIGR4 remained in the 106 to 107 CFUs/ml range. We could not gather reliable data on the
survival if even the controls were beginning to die nearly 100% after multiple hours. Therefore,
the one-hour reactions were considered sufficient for the experiment.
We are currently working on expressing and purifying clean HtrA. Small-scale and largescale inductions on new clones are being performed to clarify the presence of the protein in E.
coli lysates. If data from these experiments does not show tremendous levels of HtrA expression,
a new clone with a different signal sequence may need to be used – possibly using a S. aureus
vector rather than E. coli.
Lower levels of htrA expression in two extremely sensitive isolates compared to a highly
resistant isolate complemented the HtrA knockout data and HtrA protection results. However, a
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small sample size limits this analysis. An improvement to this analysis is currently underway.
The cts of the two sensitive isolates, the resistant isolate used in this study, and another
resistant isolate will be calculated by comparing the cts of all of these isolates to that of a control
TIGR4 ct to garner a better baseline comparison. Significantly higher levels of expression
compared to TIGR4 in both resistant isolates than sensitive isolates would provide much better
evidence in the genetic role of htrA in pneumococcal resistance to granule-mediated killing by
human neutrophils.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
With increasing rates of antibiotic resistance among pneumococcal isolates, alternative
treatments must be explored. Likewise, the ability of pneumococci to switch capsule serotypes
calls for the investigation of new vaccines with conserved protein targets. In fact, it has been
shown that the human antibody response to invasive pneumococcal disease is naturally
dependent on protein antigens rather than capsular antigens (Wilson et al., 2017). Therefore, our
lab aims to identify novel components of pneumococcal infection and to develop innovative
approaches to treating and bolstering immunity to this significant pathogen. The central
hypothesis of the research presented in this thesis was that some pneumococci have developed a
natural resistance to granule-mediated killing by neutrophils.
We concluded from the testing of sensitivity of a large panel of isolates that many strains
have developed the highly resistant phenotype and can survive neutrophil proteases. This
phenotype is not exclusive to isolates isolated from invasive sites. In fact, more isolates isolated
in the carriage state in the nasopharynx possessed the resistant phenotype. This finding may be
more reasonable given that the bacteria are much more easily transmissible during colonization
than during invasion. Moreover, the neutrophil defense has already begun during pneumococcal
colonization. We speculate that is for these reasons, the carriage isolates displayed a significantly
more resistant average survival than the invasive isolates.
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The capsule type alone was disregarded as having a substantial role in resistance as many
isolates of the same capsule type displayed highly varying sensitivity rates. As well, the isolates
representing the common capsule types seen in invasion and in the conjugate vaccines also
displayed varying sensitivity. The absence of the capsule, however, was theorized to possibly
give pneumococci an advantage to the neutrophil’s granule defense as the first panel of NESp
isolates were mostly of the highly resistant phenotype. Testing of a larger panel showed many
NESp isolates to also possess the susceptible phenotype. Still, the average sensitivity rate among
NESp isolates was significantly higher than that of the encapsulated isolates (carriage and
invasive isolates from the first study). On the other hand, the capsule knockout lab strain T4R did
not show a different sensitivity to its wildtype TIGR4. We concluded from this data that the
absence of the capsule may affect the sensitivity of pneumococci to granule-mediated killing by
neutrophils. More capsule knockout mutants of different capsule types need to be constructed
and tested to fully assess the role the presence of the capsule plays in sensitivity.
As discussed in Chapter III, the unencapsulated isolates possess different genes in
substitution for the capsule locus. However, data on the survival of strains that represent the
three different null capsule clades indicate that these differences are not significant. As well, the
survival of most of the knockout mutants of NESp isolates were not considerably different than
their wildtypes. Only a pspK knockout was significantly more resistant than its wildtype.
Furthermore, the survival of pspK- NCC isolates were not significantly different than the pspK+
isolates. Again, more isolates representing the NCC3 clade need to be tested along with further
investigation into the pspK gene and its role in survival to fully understand how unencapsulated
pneumococci are possibly more resistant than encapsulated pneumococci.
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The data on the unencapsulated isolates indicates that resistance to neutrophil granules is
a multifactorial result. Because we saw significantly more resistance in the NESp isolates than
the encapsulated isolates, we theorized that NESp isolates acquired or overexpress another factor
that may contribute to resistance without their capsules. We thought this factor must be a
secreted factor or a cell-surface factor for it to provide resistance to granules extracellularly. We
hypothesized that the protease high temperature requirement A (HtrA) may be the non-capsule
factor contributing to resistance as it has been shown to be vital to pneumococcal virulence in
response to external stresses. We found that in all but one parental strain, htrA knockouts were
more susceptible to neutrophil granules than their wildtypes.
We also found that recombinant HtrA protected TIGR4 from exposure to granules.
However, this study was concerning for a few reasons. The HtrA eluted from E. coli expression
strain lysates was not pure – it was contaminated by other proteins – nor was it concentrated. The
BSA assay to measure the concentration of protein could not differentiate the amount of HtrA
from the contaminating proteins. Therefore, the protection seen by our rHtrA may not be
trustworthy. Additionally, protection was seen by exogenous protein control BSA. At the same
concentration of BSA protein as the unclean HtrA, protection was not significant like protection
from HtrA nor was it as substantial. This could mean that we were simply overloading the
granules’ proteases with proteins and distracting them from targeting the cells. Another artifact
to this study was that the HtrA protease may have been dividing chains of pneumococci. This
separation of cells, which would lead to more CFUs on the blood agar plates, could actually be
the reason we saw such a significant increase of “survival” seen from HtrA-protected TIGR4
compared to control unexposed TIGR4. This study most certainly is being improved upon to
better elucidate the physical role of HtrA in resistance to neutrophil granules. When clean rHtrA
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samples are able to be used, another aspect of this study to be examined would be to pretreat the
HtrA with protease inhibitors before applying them to protect bacteria from the granules.
Abrogating protection via this method would imply that protease activity is needed by the
bacteria to combat the proteolytic activity of the neutrophil granules.
To complement data on the sensitivities of the htrA knockout mutants, the expression
levels of htrA were compared in sensitive isolates to a highly resistant isolate via qPCR. The
results of this study indicated that the level of the resistant isolate’s htrA expression was over
three times and nearly twice the expression levels of the two granule-susceptible isolates. This
study used a small sample size, and we plan on expanding the study to compare multiple isolates
of both phenotypes to a control expression in TIGR4. As it stands, however, this study provides
additional evidence to the substantial genetic role htrA has in resistance to granule-mediated
killing.
Understanding how Streptococcus pneumoniae evades the innate defenses of the human
immune system has already made enormous advances in modern medicine. However, morbidity
and mortality from pneumococcal disease continues to remain a major problem worldwide.
Therefore, further research to develop better strategies to combat this deadly pathogen is vital.
Our research has better illustrated the rate of sensitivity to granule-mediated killing by
neutrophils seen across pneumococcal isolates. We have also identified two factors of a
multifactorial system used by a complex organism that may contribute to the resistance of this
organism to our most abundant innate immune cell. Developing strategies to abrogate this
resistance would enhance innate immunity to this important pathogen. Optimistically, any
approaches to abrogating pneumococcal resistance may benefit the combat to other important
human pathogens.
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Table A.1
Isolate #

Data on the invasive (ABC) isolates
Site of
Isolation

Patient Age
(years)

Patient
Survived?

Known
Antibiotic
Resistance
1
Blood
10
Y
23B
None
2
Blood
48
N
12F
None
3
Blood
5
Y
23A
None
4
Blood
4
Y
15A
Tetracycline,
Erythromycin
5
Blood
17
Y
19A
Tetracycline
6
Blood
6
Y
06C
None
7
Blood
10
Y
16F
None
8
Blood
37
Y
35B
None
9
Blood
3
Y
06C
Erythromycin
10
Blood
27
Y
18C
None
11
Blood
12
Y
23F
None
12
CSF
25
Y
06B
None
13
Blood
10
Y
19A
None
14
Blood
8
Y
15B
None
15
Blood
37
Y
12F
None
16
Blood
25
N
15C
None
17
Blood
61
Y
19F
None
18
Blood
14
Y
12F
None
19
Blood
37
Y
06C
None
20
Blood
1
Y
15B
None
21
Blood
33
Y
3
None
22
Blood
6
Y
06C
None
23
Blood
9
N
06A
Erythromycin
Table 2.1 provides known data on all 23 of the invasive (ABC) isolates used provided by the
CDC. Data provided includes the tissue the isolates were extracted from (blood or cerebral spinal
fluid), the age of the patients the isolates were extracted from (in years), if the patients survived
(yes or no), the capsular serotype of the isolates, and what antibiotics the isolates have known
resistance to.
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Serotype

Table A.2

Data on the carriage (SPN) isolates
Isolate #

Site of Isolation

Known Antibiotic
Resistance
1
Nasopharynx
Erythromycin
2
Nasopharynx
None
3
Nasopharynx
Streptomycin
4
Nasopharynx
Tetracycline, Erythromycin
5
Nasopharynx
Tetracycline
6
Nasopharynx
None
7
Nasopharynx
None
9
Nasopharynx
None
11
Nasopharynx
None
12
Nasopharynx
None
13
Nasopharynx
None
14
Nasopharynx
Erythromycin
15
Nasopharynx
None
31
Nasopharynx
None
Table 2.2 provides known data on all 14 carriage (SPN) isolates used. Data provided includes the
tissue the isolates were extracted from and what antibiotics the isolates have known resistance to.
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Table A.3

Data on NESp isolates, their mutants, TIGR4, and its capsule knockout mutant
T4R

Strain Name

Type of Strain

Site of Isolation
(only for
isolates)

Known
Antibiotic
Resistance

Nasopharynx

Parental
Strain and
Gene Deleted
(only for
mutants)
N/A

MNZ11

Isolate

MNZ41

Isolate

Nasopharynx

N/A

None

MNZ67

Isolate

Nasopharynx

N/A

None

MNZ85

Isolate

Nasopharynx

N/A

None

NCC1A

Isolate

Nasopharynx

N/A

None

NCC1B

Isolate

Nasopharynx

N/A

None

NCC1D

Isolate

Nasopharynx

N/A

None

NCC1E

Isolate

Nasopharynx

N/A

None

NCC1F

Isolate

Nasopharynx

N/A

None

NCC1G

Isolate

Nasopharynx

N/A

None

NCC1H

Isolate

Nasopharynx

N/A

None

NCC2A

Isolate

Nasopharynx

N/A

None

NCC2B

Isolate

Nasopharynx

N/A

None
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None

Table A.3 (continued)
Strain Name

Type of Strain

Site of Isolation
(only for
isolates)

Known
Antibiotic
Resistance

Nasopharynx

Parental
Strain and
Gene Deleted
(only for
mutants)
N/A

NCC2C

Isolate

NCC2D

Isolate

Nasopharynx

N/A

None

NCC2E

Isolate

Nasopharynx

N/A

None

NCC2F

Isolate

Nasopharynx

N/A

None

NCC3A

Isolate

Nasopharynx

N/A

None

NCC3B

Isolate

Nasopharynx

N/A

None

JLB01

Mutant

N/A

MNZ41; aliC

None

None

and aliD
JLB10

Mutant

N/A

MNZ41;

None

cbpAC
LEK05

Mutant

N/A

MNZ67; pspK

None

LEK08

Mutant

N/A

MNZ85; aliC

None

and aliD
PIP01

Mutant

N/A

MNZ67; potD

None

TIGR4

Laboratory

N/A

N/A

None

N/A

TIGR4; cps

Chloramphenicol

Strain
T4R

Mutant

genes
Table 3.1 provides data on all 19 NESp isolates used, five of their mutants, TIGR4, and T4R.
Data provided for each strain includes type of strain (isolate, mutant, or laboratory strain), the
site of isolation (only for isolates), the parental strain and gene deleted only in mutants, and what
antibiotics the strains have known resistance to.
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Table A.4

Primers
Primer Name
ERM Forward

Primer Sequence
GGA AAT AAG ACT TAG
AAG CAA AC
ERM Reverse
CCA AAT TTA CAA AAG
CGA CTC
HtrA Forward
AAT TCA AAC ATA TGG
AGG CAA A
HtrA Reverse
CTG TTG ATG AAG CAA
TCT CTT TGT
HtrA 2
CCA TGA TTC TAC ACT
AAC AC
HtrA 5
CAC CAT AAC TCA ACT
AAC TCA AAA AAG
HtrA RT Forward
TCG GAA GAT GGA CAA
GCT ATT T
HtrA RT Reverse
CCG ATA ACC TGC CCT
TGA ATA
HtrA-KO 1
GAA GGC GAA TGC TCT
ATC CA
HtrA-KO 2
GTT TGC TTC TAA GTC
TTA TTT CCC ATA TTT
GCC TCC ATA TG
HtrA-KO 3
GAG TCG CTT TTG TAA
ATT TGG TTG ACA TCT
ATG TAA AGA AAG C
HtrA-KO 4
AGC CTT ATT TCA GGC
TGT TG
Gyrase Forward
ATG AAC TCT TGG CTC
TGA TTG
Gyrase Reverse
CAA CTC TGT ACG GCG
CTT AT
Table 4.1 provides data on all of the primers used in this study. The data includes the primer
name and sequence.
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Table A.5

Data on strains and mutants used in HtrA knockout experiments

Strain Name

Type of Strain

Parental Strain and
Gene Deleted (only
for mutants)

Known Antibiotic
Resistance

T4R

Laboratory Strain and
Mutant

TIGR4; cps genes

Chloramphenicol

JAT97

Mutant

T4R; htrA

Chloramphenicol,
Erythromycin

TIGR4

Laboratory Strain

N/A

None

JHJ1

Mutant

TIGR4; htrA

Erythromycin

JAT103

Mutant

TIGR4; htrA

Erythromycin

EF3030

Laboratory Strain

N/A

None

JHJ2

Mutant

EF3030; htrA

Erythromycin

ABC7

Isolate

N/A

None

JAT111

Mutant

ABC7; htrA

Erythromycin

ABC10

Isolate

N/A

None

JAT110

Mutant

ABC10; htrA

Erythromycin

Table 4.2 provides data on all of the laboratory strains, isolates, and mutants used in the HtrA
knockout studies. Data provided on each strain includes the type of strain (laboratory strain,
isolate, or mutant), the parental strain and gene deleted only for mutants, and what antibiotics the
strain have known resistance to.
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APPENDIX B
FIGURES
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Figure B.1

Purification of PMNs using PolymorphprepTM

MC = mononuclear cells; PMNs = polymorphonuclear leukocytes. This illustration shows the
result of centrifuging blood over Polymorphprep solution. Picture on right shows an actual
separation in a 15 ml conical tube (taken from PolymorphprepTM Application Sheet).

Figure B.2

Sensitivity to granule-mediated killing of first six invasive isolates

Roughly 106 pneumococci per mL were exposed to granules extracted from human neutrophils
for one hour at 37ºC. Concentration counts were quantitated and compared to concentration
counts of the same concentration of pneumococci, that were not exposed to granules. Data shown
are the means ± standard deviation (SD) for control and experimental counts of six invasive
isolates – ABC1 (blue), ABC2 (red), ABC3 (green), ABC4 (purple), ABC5 (orange), and ABC6
(teal). Asterisks (*) indicate strains significantly killed by degranulate.
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Figure B.3

Sensitivity to granule-mediated killing of ABC 7-12 isolates

Data shown are the means ± SD for control and experimental counts of six invasive isolates.
Shown are ABC7 (blue), ABC8 (red), ABC9 (green), ABC10 (purple), ABC11 (orange), and
ABC12 (teal). Asterisks (*) indicate strains significantly killed by degranulate.

Figure B.4

Sensitivity to granule-mediated killing of ABC 13-18 isolates

Data shown are the means ± SD for control and experimental counts of six invasive isolates.
Shown are ABC13 (blue), ABC14 (red), ABC15 (green), ABC16 (purple), ABC17 (orange), and
ABC18 (teal). Asterisks (*) indicate strains significantly killed by degranulate.
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Figure B.5

Sensitivity to granule-mediated killing of final five invasive isolates

Data shown are the means ± SD for control and experimental counts of the last five invasive
isolates. Shown are ABC19 (blue), ABC20 (red), ABC21 (green), ABC22 (purple), and ABC23
(orange). Asterisks (*) indicate strains significantly killed by degranulate.

Figure B.6

Sensitivity of all 23 invasive isolates to degranulate killing by human neutrophils.

Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all 23 invasive isolates. Asterisks (*) indicate strains
significantly killed by degranulate.
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Figure B.7

Sensitivity to granule-mediated killing of first six carriage isolates

Data shown are the means ± SD for control and experimental counts of six carriage isolates –
SPN1 (blue), SPN2 (red), SPN3 (green), SPN4 (purple), SPN5 (orange), and SPN6 (teal).
Asterisks (*) indicate strains significantly killed by degranulate.

Figure B.8

Sensitivity to granule-mediated killing of five carriage isolates

Data shown are the means ± SD for control and experimental counts of five carriage isolates.
Shown are SPN7 (blue), SPN9 (red), SPN11 (green), SPN12 (purple), and SPN13 (orange).
Asterisks (*) indicate strains significantly killed by degranulate.
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Figure B.9

Sensitivity to granule-mediated killing of final three carriage isolates

Data shown are the means ± SD for control and experimental counts of three carriage isolates.
Shown are SPN14 (blue), SPN15 (red), and SPN31 (green). Asterisks (*) indicate strains
significantly killed by degranulate.

Figure B.10 Sensitivity of all 14 carriage isolates to granule-mediated killing by human
neutrophils
Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all 14 carriage isolates. Asterisks (*) indicate strains
significantly killed by degranulate.
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Figure B.11 Average sensitivity of invasive isolates and carriage isolates
The average sensitivities of invasive isolates and carriage isolates were assessed with an
unpaired two-tailed t test. Asterisk (*) indicates that a significant difference was found between
the average sensitivities of the two types of isolates.

Figure B.12 Sensitivity to granule-mediated killing of first four unencapsulated isolates
Roughly 106 pneumococci per ml were exposed to granules extracted from human neutrophils
for one hour at 37ºC. Concentration counts were quantitated and compared to concentration
counts of the same concentration of pneumococci, that were not exposed to granules. Data shown
are the means ± standard deviation (SD) for control and experimental counts of four
unencapsulated isolates – MNZ41 (blue), MNZ11 (orange), MNZ85 (purple), and MNZ67
(green).
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Figure B.13 Sensitivity of the first 4 NESp isolates to granule-mediated killing
Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of ten unencapsulated isolates. Asterisk (*) indicates the one strain
significantly killed by degranulate.

Figure B.14 Sensitivity to granule-mediated killing of first five NCC isolates
Data shown are the means ± SD for control and experimental counts of the first five NCC
isolates. Shown are NCC1A (blue), NCC1B (red), NCC1D (green), NCC1E (purple), and
NCC1F (orange). Asterisks (*) indicate strains significantly killed by degranulate.
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Figure B.15 Sensitivity to granule-mediated killing of five more NCC isolates
Data shown are the means ± SD for control and experimental counts of five NCC isolates.
Shown are NCC1G (blue), NCC1H (red), NCC2A (green), NCC2B (purple), and NCC2C
(orange). Asterisks (*) indicate strains significantly killed by degranulate.

Figure B.16 Sensitivity to granule-mediated killing of last five NCC isolates
Data shown are the means ± SD for control and experimental counts of five NCC isolates.
Shown are NCC2D (blue), NCC2E (red), NCC2F (green), NCC3A (purple), and NCC3B
(orange). Asterisk (*) indicates the strain significantly killed by degranulate.
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Figure B.17 Percent survivals of all NCC isolates to granule-mediated killing by neutrophils
Percent survival of each isolate was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all 15 NCC isolates. Asterisks (*) indicate strains significantly
killed by degranulate.

Figure B.18 Average sensitivity of encapsulated isolates and unencapsulated isolates
The average sensitivities of encapsulated isolates and unencapsulated isolates were assessed with
an unpaired two-tailed t test. Asterisk (*) indicates that a significant difference was found
between the average sensitivities of the two types of isolates.
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Figure B.19 Sensitivity to granule-mediated killing of TIGR4 and T4R
Data shown are the means ± standard deviation (SD) for control and experimental counts of
TIGR4 (blue) and its capsule knock-out mutant T4R (red). Asterisks (*) indicate strains
significantly killed by degranulate.

Figure B.20 Percent survival of TIGR4 and T4R to granule-mediated killing by neutrophils
Percent survival of each strain was calculated by dividing the concentration counts of
experimental reactions by control reactions and multiplying by 100%. Data shown are the means
± SD for the percent survival of all TIGR4 and T4R.
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Figure B.21 Sensitivity to granule-mediated killing of six mutants of unencapsulated isolates
Data shown are the means ± SD for control and experimental counts of six mutants of NESp
isolates. Shown are JLB01 (blue), JLB10 (red), LEK08 (green), LEK05 (orange), and PIP01
(teal). Asterisk (*) indicates the strain significantly killed by degranulate.

Figure B.22 Percent survivals of all NESp wildtypes versus their mutants
Data shown are the means ± SD for the percent survival of four NESp isolates and their mutants.
Asterisk (*) indicates the only significant difference in percent survivals of wildtype and mutant.
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Figure B.23 Average survival of NCC1, NCC2, and NCC3 isolates
The average sensitivities of all three clades of NCC isolates were assessed with one-way
ANOVA. No significant difference was found among the three clades of isolates.

Figure B.24 Electrophoresis gel of wildtype pneumococcal strains and their htrA knockouts
Ex Taq PCR screening was conducted on wildtype and mutant pneumococci using Erm forward
and reverse primers. Bands indicate presence of Erm cassette in place of htrA.
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Figure B.25 Survival of T4R and its htrA-deficient mutant JAT97 post-exposure to granules
Roughly 106 pneumococci per ml were exposed to granules extracted from human neutrophils
for one hour at 37ºC. Data shown are the means ± standard deviation (SD) for control and
experimental counts of T4R (blue) and JAT97 (red). Asterisks (*) indicate strains significantly
killed by degranulate.

Figure B.26 Percent survival of T4R and JAT97 to granule-mediated killing by neutrophils
Data shown are the means ± SD for the percent survival of T4R and JAT97. Asterisk (*)
indicates that JAT97 was significantly more susceptible to degranulate killing than the wildtype
T4R.
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Figure B.27 Survival of wildtype pneumococci and their htrA-deficient mutants to granules
Data shown are the means ± standard deviation (SD) for control and experimental counts of two
wildtype pneumococcal strains and their htrA mutants. Shown are T4 (blue), JHJ1 (red),
JAT103 (green), EF3030 (purple), and JHJ2 (orange). Asterisks (*) indicate strains significantly
killed by degranulate.

Figure B.28 Sensitivity of wildtype pneumococci and their htrA-deficient mutants
Data shown are the means ± SD for the percent survival of TIGR4, JHJ1, JAT103, EF3030, and
JHJ2. Asterisks (*) indicate significant differences in wildtype and mutant survivals.
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Figure B.29 Electrophoresis gel of wildtype pneumococcal isolates and their htrA knockouts
Ex Taq PCR screening was conducted on wildtype and mutant pneumococci using Erm forward
and reverse primers. Bands indicate presence of Erm cassette in place of htrA.

Figure B.30 Concentrations of resistant invasive isolates and their htrA-deficient mutants postexposure to degranulate
Data shown are the means ± standard deviation (SD) for control and experimental counts of two
wildtype pneumococcal invasive isolates and their htrA mutants. Shown are ABC7 (blue),
JAT111 (red), ABC10 (green), and JAT110 (purple). Asterisk (*) indicates the strain
significantly killed by degranulate.
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Figure B.31 Sensitivity of wildtype invasive isolates and their htrA-deficient mutants
Data shown are the means ± SD for the percent survival of ABC7, JAT111, ABC10, and
JAT110. Asterisk (*) indicates that a significant difference of survival was found between
wildtype and mutant.

Figure B.32 Gel electrophoresis of nine transformants from the transformation of pHtrA into
BL-21 E. coli
Nine transformants were screened with HtrA primers 2 and 5 and ran on a .8% agarose gel. All
transformants screened except for numbers 4 and 8 were positive for the HtrA plasmid. The first
two were selected to grow for purification of recombinant HtrA.
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Figure B.33 Survival of TIGR4 exposed to granules and rHtrA or BSA
106 pneumococci per ml were exposed to granules extracted from human neutrophils and either
HtrA or BSA for one hour at 37ºC. Data shown are the means ± standard deviation (SD) for a
zero-hour control (blue), a one-hour control (red), a degranulate-exposed (green), and
degranulate-exposed and HtrA-protected (purple), and a degranulate-exposed and BSA-protected
(orange) TIGR4. Asterisks (*) indicate significant differences in CFUs.

Figure B.34 Percent survival of TIGR4 exposed to granules and HtrA or BSA
Data shown are the means ± SD for the percent survival of TIGR4 to degranulate and TIGR4
exposed to degranulate and HtrA or BSA. Asterisk (*) indicates a significant difference in
survival.
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Figure B.35 Expression of ABC13 and ABC14 compared to ABC7
qPCR was conducted on ABC7, ABC13, and ABC14 targeting htrA. ct was calculated for the
isolates 13 and 14 compared to ABC7 using mean cts of multiple runs. Shown are expression
levels of ABC13 (red) and ABC14 (green) related to ABC7 (blue).
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